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Summary 
Cytochrome P450 monooxygenases (P450s) represent a ubiquitous group of 
enzymes with a broad substrate spectrum. Their ability to catalyze a variety of 
reactions, e.g. detoxification of insecticides, makes them interesting enzyme 
candidates with enormous industrial potential. Unfortunately, they cannot be fully 
utilized due to their complex characteristic like their necessity of a cytochrome P450 
reductase (CPR) for the electron transfer from NADPH. Furthermore, the P450s and 
CPRs contain membrane anchors leading to insoluble protein. These two factors 
represent challenges for their artificial production and consequently purification and 
whole-cell applications. 
The aim of this study was to overcome those challenges by construction of P450-
fusion enzymes. Those fusion enzymes were designed based on the bacterial 
CYP102A (BM3) from Bacillus megaterium, which is a known natural fusion enzyme 
and does not possess any membrane anchor. Our fusion enzymes are composed of 
a changeable insect P450, a variable BM3 linker, BM3 CPR (BMR) and a C-terminal 
6xHis-tag. For the first time, three different insect fusion enzymes of the CYP6 family 
(CYP6A1-BMR, CYP6G1-BMR and CYP6AE14-BMR) and of the CYP4G subfamily 
(CYP4G1-BMR, CYP4G2-BMR and CYP4GF-BMR) were constructed. Such a fusion 
made it possible to produce insect CYP6s recombinantly in an Escherichia coli 
system and to purify those without the use of detergents. Suitable LC- and GC-MS 
methods to characterize the purified enzymes were established in order to verify 
their ability to oxygenize the substrates imidacloprid and aldrin. 
A whole-cell approach was established to exclude the purification process as reason 
of CYP6-BMR construct inactivity. In this study it was shown that acyl-ACP reductase 
and aldehyde decarbonylase from the blue algae Nostoc punctiforme can be pro-
duced recombinantly in E. coli. It was demonstrated that they are able to catalyze 
the transformation of E. coli produced long-chain fatty acids to long-chain alkanes. 
In the next step the aldehyde decarbonylase was replaced by the CYP4G fusion 
constructs. Thereby the acyl-ACP reductase and the fusion construct generate a 
whole-cell system for alkane production. For the aldehyde and alkane detection a 
SPME-GC-MS method was established. 
Summary 
 
 
2 
 
The findings of the present study concerning the construction of novel insect P450-
fusion enzymes as well as the established analytical methods serve as a basis for 
further insect P450 characterization and biocatalyst development.  
Zusammenfassung 
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Zusammenfassung 
Cytochrom-P450-Monooxygenasen (CYPs) bilden eine in vielen Organismen vor-
kommende Enzymgruppe mit einem großen Substratspektrum. Sie besitzen eine 
große Reaktionsvielfalt, wie zum Beispiel die Entgiftung von Insektiziden, was sie zu 
besonders interessanten Kandidaten für die industrielle Anwendung macht. 
Allerdings können CYPs auf Grund ihrer komplexen Eigenschaften, wie die 
Notwendigkeit einer Cytochrom-P450-Reduktase (CPR) für den Elektronentransfer 
von NADPH, nicht vollständig genutzt werden. Darüber hinaus sind CYPs und CPRs 
auf Grund ihrer Membrananker unlöslich. Diese zwei Faktoren stellen Herausforde-
rungen für ihre artifizielle Produktion und anschließende Aufreinigungs- und 
Ganzzell-Anwendungen dar. 
Das Ziel dieser Studie war es, die genannten Schwierigkeiten durch die Konstruktion 
von CYP-Fusionsenzymen zu überwinden. Die Fusionsenzyme wurden auf 
Grundlage der bakteriellen CYP102A1 (BM3) aus Bacillus megaterium, einem natür-
lichen Fusionsenzym ohne Membrananker, konstruiert. Die generierten Fusionskon-
strukte bestehen aus einer austauschbaren Insekten-CYP, einem variablen BM3-
Linker, der BM3-CPR (BMR), und einem C-terminalem 6xHis-tag. Zum ersten Mal 
wurden drei verschiedene Insekten-Fusionsenzyme der CYP6-Familie (CYP6A1-
BMR, CYP6G1-BMR und CYP6AE14-BMR) und der CYP4G-Unterfamilie (CYP4G1-
BMR, CYP4G2-BMR und CYP4GF-BMR) konstruiert. Diese Fusion ermöglichte die 
rekombinante Insekten-CYP6-Produktion in Escherichia coli sowie die Aufreinigung 
ohne den Einsatz von Detergenzien. Mit dem Ziel die Fähigkeit der aufgereinigten 
Enzyme, die Oxidation der Substrate Imidacloprid und Aldrin, nachzuweisen, wurden 
passende LC- und GC-MS-Methoden für die Charakterisierung etabliert. 
Es wurde ein Ganzzell-Ansatz entwickelt, um den Aufreinigungsprozess als Grund 
für die CYP6-Inaktivität ausschließen zu können. In dieser Studie wurde gezeigt, 
dass die aus der Blaualge Nostoc punctiforme stammenden Enzyme Acyl-ACP-
Reduktase und Aldehyddecarbonylase rekombinant zusammen in E. coli produziert 
werden können und, dass sie die von E. coli produzierten langkettigen Fettsäuren in 
langkettige Alkane umwandeln können. In einem nächsten Schritt wurde die Aldehyd-
decarbonylase durch ein CYP4G-Fusionskonstrukt ersetzt. Dadurch generieren die 
Acyl-ACP-Reduktase und das Fusionskonstrukt ein Ganzzell-System zur 
Alkanproduktion. Zur Detektion der Aldehyde und Alkane wurde eine SPME-GC-MS-
Methode etabliert. 
Zusammenfassung 
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Die Ergebnisse dieser Studie, welche die Konstruktion neuer Insekten-CYP-Fusions-
enzyme, sowie die etablierten Methoden, dienen als Grundlage für die weitere 
Charakterisierung und biokatalytische Entwicklung von Insekten-CYPs. 
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Synopsis 
1 Introduction 
1.1 Cytochrome P450 monooxygenases 
Cytochrome P450 monooxygenases (P450) are a ubiquitous superfamily of mixed 
function oxidases [1]. The P450 superfamily is one of the largest and oldest gene 
superfamilies [1]. P450s are heme-thiolated monooxygenases found in all biological 
kingdoms and fulfill various roles in their hosts. P450s are involved in the metabolism 
of xenobiotics and drugs [2], steroid biosynthesis [3 ] and the assimilation of carbon 
sources for growth [4 ]. They were first discovered by Garfinkel and Klingenberg and 
were identified and isolated from mammalian liver microsomes in 1964 by Omura and 
Sato [5-7]. There are over one thousand P450 families known with around 21000 
different P450s and the numbers are still increasing [8 ]. This indicates their 
importance for all forms of life. The nomenclature of P450s was introduced in 1987 
by Nebert et al.. The members of this superfamily, for example CYP6A1, are 
indicated with a CYP prefix, the following number (6) shows the family, the letter (A) 
the subfamily and the number (1) the enzyme [9]. Members of one P450 family share 
>40% amino acid sequence identity, within wide variation across the different 
families. All P450s form similar secondary and tertiary structures [10-12]. The heme b 
cofactor forms the catalytic reaction center of the P450. The heme contains an iron 
atom at its center which is bound to a protoporphyrin ring by four nitrogen ligands, 
which forms a planar structure. It is coordinated by an evolutionary conserved axial 
cysteine ligand, FXXGXXXCXG, which is located towards the C-terminus of the 
protein [1]. The iron is often associated with water as a sixth ligand. Heme is 
responsible for a Soret band absorbance at 420 nm when it is coordinated to water. 
The absorbance signal shows a typical shift to 450 nm when carbon monoxide is 
bound at the opposite axial position, as shown in Figure 1-1. This led to the name 
P450 which stands for Pigment 450 [5]. 
Introduction 
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Figure 1-1:Typical absorption spectrum of a P450 enzyme. The light grey line shows the 
oxidized (ferric state) of the enzyme with Amax at 420 nm.  The black line shows the 
dithionite-reduced Fe(II)–CO complex of the enzyme with Amax at 450 nm [13]. Reproduced 
from A. W. Munro, H. M. Girvan, K. J. McLean, Natural Product Reports 2007, 24, 585-609 
with permission of The Royal Society of Chemistry. 
 
1.2 P450 reactions 
P450s cannot catalyze a reaction on their own as they need to accept electrons from 
a redox partner, shown in Figure 1-2. The reaction requires two reducing equivalents, 
derived from a nicotinamide cofactor [14]. Other prosthetic groups, for example FAD 
and FMN, which are derived from riboflavin, serve as electron transfer centers.  
 
Figure 1-2: Schematic representation of the P450 redox partner (CPR) interaction. 
P450s are able to catalyze unique one-step C-H bond oxidations by a subsequent 
insertion of one oxygen atom into the substrate and the other oxygen atom forming 
water [15-16]. They can catalyze various reactions (Figure 1-3). The P450 substrates 
and reactions cannot be determined from their evolutionary proximity to other P450s 
or their sequence [1 ]. Most common is the monooxygenation, which leads to a 
hydroxylation or epoxidation at a carbon center, shown in Figure 1-3 a. Less common 
Introduction 
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is the oxidation and dealkylation at a heteroatom and complex reactions like single 
electron reductions, desaturations and ring modifications alongside typical 
oxidations [17], shown in Figure 1-3 b. All those reactions are difficult to realize by 
synthetic chemistry where regio- and stereo-selectivity is not easily achieved. This 
is one reason why the research on P450s is of interest for industrial applications. 
 
 
Figure 1-3: Reactions catalyzed by P450 monooxygenases. (a) Common and (b) uncommon 
reactions [18 ]. David C. Lamb, Michael R. Waterman, Unusual properties of the cytochrome 
P450 superfamily, Philosophical Transactions B, The Royal Society, 2013, 368, 1612, by 
permission of the Royal Society 
 
1.3 Insect P450s 
P450s are common in insects, comprise over a hundred different genes [19] and form 
an extremely important metabolic system. They are involved in the metabolism of 
endogenous compounds and xenobiotics [20]. P450s show high similarity in reaction 
mechanism and structure with the well-studied mammalian P450s. Insect P450s can 
be either microsomal or mitochondrial. Microsomal P450s depend on a P450 
reductase or cytochrome b5 or both as electron donor whereas mitochondrial P450s 
depend on an adrenodoxin-like ferredoxin coupled to adrenodoxin reductase as 
electron donor. Six P450 families are known in insects, five of them are insect 
Introduction 
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specific families (CYP6, 9, 12, 18 and 28). They have a variety of function, caused 
by a diversity in structure [1 ]. Insect P450s are involved in growth, development, 
feeding, pesticide resistance, and tolerance to plant toxins. The expression levels of 
P450s in insects can vary across different life stages [21] and they are present in 
several tissues such as Malpighian tubules, fat body and midgut [22]. There is no 
clear phylogenetic distinction between P450s relevant for detoxification and those 
involved in the physiological homeostasis, which leads to the assumption that P450s 
can alter their function over evolutionary time [22]. Research on insect P450s is 
focused on metabolism, synergism and resistance [22]. Determination of their catalytic 
competence is difficult, because of their variability and due to the fact that they are 
membrane-bound and require electron-donating partners [1 ]. The membrane anchor 
inhibits the formation of soluble protein and a reconstitution system containing 
detergents and phospholipids is required for the P450 CPR interaction [23]. The 
standard procedures to determine the catalytic competence of P450s are 
heterologous expression and reconstitution experiments [24]. Molecular samples 
obtained from resistant strains show constitutive overexpression of P450 genes [1]. 
A common mechanism for insects becoming resistant to insecticides is the P450-
mediated metabolism [24]. The first purified insect P450 reductase from Musca 
domestica is similar to mammalian P450 reductases [25]. The first cloned insect P450 
was from the CYP6 family. CYP6A1 is a xenobiotic-metabolizing P450 from Musca 
domestica. It was produced in a reconstituted E. coli system and aldrin and 
heptachlor were identified as substrates [26]. CYP6A1 has a spacious heme active 
site which is compatible with several substrate geometries and orientations [27]. 
CYP6G1 from Drosophila melanogaster can be classified as a multi-pesticide 
associated enzyme, since it is linked to resistance towards various structurally non 
related compounds [28]. A very unusual reaction for a P450 enzyme is the 
decarbonylation of aldehydes which forms alkanes by CO2 cleavage (Figure 1-4). 
The formation of hydrocarbons is well known from insects, since they are important 
for the prevention of desiccation and also function as contact pheromones [29]. The 
first P450 shown to be able to catalyze this reaction was CYP4G1 from Drosophila 
melanogaster [30]. 
Introduction 
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Figure 1-4: Mechanism of reaction catalyzed by CYP4G1 with aldehyde as substrate and 
alkane and CO2 as products. The colors indicate the positions of isotopically-labeled 
substrates used in the study. Reprinted (adapted) with permission from (E. N. G. Marsh, M. 
W. Waugh, ACS Catalysis 2013, 3, 2515-2521.). Copyright (2013) American Chemical 
Society. [31]. 
 
1.4 P450 Optimization 
P450 engineering focused on optimization of the heme domain, to improve or expand 
its catalytic performance which is limited by the need of an electron-donating partner, 
dependency on NADPH and the fact that the P450s are membrane-bound [32]. In order 
to overcome these limitations, different approaches like enzymatic [33] or 
photochemical [34] cofactor regeneration or chemical [35] and electrochemical [36] 
cofactor substitution, were developed. Another approach is the construction of 
artificial P450 fusion enzymes. P450 fusion enzymes are self-sufficient enzymes, 
where the heme domain is covalently linked to a reductase system [37]. In previous 
studies this was achieved in three different ways. 1. “LICRED” is a method developed 
by Bruce and coworkers for generating redox-self-sufficient P450s in a high-
throughput manner. A vector containing the reductase domain of CYP116B2 (natural 
fusion P450) in front of a ligation-independent cloning (LIC) site allows rapid 
insertion of P450 genes [38] [39]. 2. “PUPPET” is a system developed by Nagamune 
and colleagues using a platform made of three distinct proliferating cell nuclear 
agents (PCNAs) which form a heterodimer called “PUPPET”. This is an approach to 
bring the heme group and its redox partners in close proximity to each other to 
increase the efficiency of the electron transport [40] [41]. 3. The “Molecular Lego” 
approach was established by Gilardi creating chimeric P450-reductase fusion using 
the natural fusion enzyme CYP102A1 [42]. This method is the basis of the work 
presented here for the construction of insect P450 fusion enzymes. 
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1.4.1 CYP102A1 
CYP102A1 (BM3) is derived from Bacillus megaterium where it is involved in the fatty 
acid metabolism. BM3 is a self-sufficient fatty acid hydroxylase which is able to 
catalyze reactions without requiring the assistance of additional proteins. BM3 is a 
natural fusion protein where the catalytic P450 is covalently attached to the N-
terminus of the redox domain by a linker on the same peptide chain, which entirely 
makes it a class II P450 system [43], as shown in Figure 1-5, typical of microsomal 
eukaryotic P450s [44]. The redox domain (BMR) is 66 kDa in size and binds two 
flavins, FAD and FMN, as prosthetic groups. The BMR closely resembles the 
eukaryotic CPR since it also uses FAD and FMN [43]. It has approximately 33% 
sequence identity to the mammalian hepatic CPR. The P450 domain is 55 kDa in 
size and has approximately 25% sequence identity to the fatty acid ω-hydroxylases 
of the CYP family IV [45].  
 
Figure 1-5: Schematic representation of the natural P450-redox partner fusion enzyme BM3. 
The electron transfer from the reductase domain to the heme domain influences the 
enzyme activity. The linker length is of more importance for the enzyme activity than 
the amino acid composition because it determines the correct position of both 
domains towards each other [46]. BM3 has the highest known substrate turn-over rate 
of a P450. It is able to oxidize arachidonic acid at a rate of 5000 min -1 [47]. It was 
shown that the P450 and reductase domain retain their activity when being separated 
from each other, but the product formation is decreased. They form similar region-
isomeric products as the full length enzyme [48]. Due to its self-sufficiency, its high 
substrate turn-over rate and the fact that it is not membrane bound BM3 serves as 
an important model for CYP research [43]. 
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1.4.2 Molecular Lego 
The “Molecular Lego” method was developed to create soluble new artificial fusion 
enzymes with a novel catalytic function [49].  
 
 
Figure 1-6: Schematic representation of the “Molecular Lego” principle to construct soluble, 
self-sufficient fusion human P450-BMR enzymes. Figure modified from Sadeghi and 
Gilardi [32 ]. 
This tool was used successfully for the creation of soluble, self-sufficient human 
P450-BMR fusion enzymes [50]. BM3 was divided into three building blocks, the P450 
heme domain, the linker domain and the BMR domain. For the creation of human 
P450-BMR fusion enzymes the BM3-P450 heme domain was cleaved off and 
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replaced by a human P450 enzyme. The solubility of the enzyme was achieved by 
N-terminal modifications (removal of the hydrophobic N-terminal membrane anchor 
domain) of the former insoluble P450. The process is shown in Figure 1-6. Due to 
those changes a purification of the constructs without the use of detergents was 
possible and similar catalytic activities to the wild-type P450s were shown [50]. The 
BMR domain shows a similar catalytic mechanism to the CPR of Musca domestica [1 ]. 
  
Aims and Objectives 
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2 Aims and Objectives 
Insect P450s play important roles in insect growth, development, feeding, tolerance 
to plant toxins or pesticide resistance [21]. Their direct participation in pesticide 
resistance as well as their ability to catalyze various reactions attracts researchers 
from different fields and makes insect P450s interesting research candidates. A key 
challenge in insect P450s research is their complex characteristic they also share 
with human P450s. The crucial steps to overcome are (i) the necessity of a 
cytochrome P450 reductase (CPR) for the electron transfer from NADPH and (ii) 
P450s and CPR membrane anchors. For human P450s these problems were 
overcome by the ‘Molecular Lego’ approach. This approach enabled the creation of 
soluble, self-sufficient human P450-BMR fusion enzymes [50].  
The aim of this project was to apply the same “Molecular Lego” approach for the 
creation of new insect P450-BMR fusion enzymes. The specific insect P450s were 
selected based on the P450s insect origin (e.g. CYP4G from F. auricularia), 
sequence availability as well as their potential substrates (e.g. CYP6 is involved in 
insecticide metabolism). Due to the relatively short production time and high yields 
E. coli expression system was chosen for recombinant production of fusion enzymes. 
Due to the complexity of P450s, two different production approaches were tested. 
The goal of the first approach was to produce the CYP6-BMR constructs in E. coli 
with subsequent detergent free purification of soluble enzyme. The second approach 
focused on the establishment of a whole cell coexpression system, which comprised 
of the CYP4G-BMR construct and the blue algae acyl-ACP reductase. Specific 
photometric activity assays as well as GC- and LC-MS methods for detection of 
relevant P450s substrates and products were established to further characterize the 
produced enzymes.  
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3 Methods 
3.1 Gene synthesis 
All genes were synthesized with a C-terminal His6-tag (GHHHHHH) and E. coli K12 
codon optimized (MWG Eurofins). The genes encoding for BM3 and insect P450 
genes were flanked by BsaI sites for restriction digestion and ligation into the pASK-
IBA33plus vector. During the synthesis of the gene encoding for BM3, KpnI, XbaI, 
and SalI sites were added to enable the removal of the BM3 P450 domain. The XbaI 
site is located 41 base pairs upstream of the start codon, the KpnI site 156 base 
pairs downstream of the start codon and the SalI site inside the linker, which is 50 
amino acids long. The genes encoding for CYP4G1 and CYP4G2 were ordered with 
a 22 amino acids truncated N-terminus. With this approach six plasmids have been 
generated: i) pASK-IBA33_BM3, ii) pASK-IBA33_CYP6A1, iii) pASK-IBA33_ 
CYP6G1, iv) pASK-IBA33_CYP6AE14, v) pASK-IBA33_CYP4G1_d22, vi) pASK-
IBA33_CYP4G2_d22. In addition the gene encoding for aldehyde decarbonylase 
were purchased with an N-terminal His6-tag, also E. coli K12 codon optimized. The 
gene was flanked by BsaI sites for restriction digestion and ligation into the pASK-
IBA33plus vector creating the plasmid pASK-IBA33_aldehyde decarbonylase. 
Moreover the gene encoding for acyl-ACP reductase was commercially obtained with 
a C-terminal His6-tag and E. coli K12 codon optimized. The gene was flanked by an 
NcoI site at the N-terminal site of the gene and an XhoI site at the C-terminal site of 
the gene for restriction digestion and ligation into the pCDFDuet-1 vector. By this 
the second open reading frame and the associated promoter were eliminated 
creating the plasmid pCDFDuet-1_acyl-ACP reductase. 
 
3.2 PCR 
For the N- and C- terminal attachment of restriction enzyme sites to a gene a PCR 
was performed under the following conditions with either Pfu polymerase or Phusion 
Flash Master Mix (Table 3-1, Table 3-2, Table 3-3 and Table 3-4). 
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Table 3-1: Reaction Setup for PCR reactions using Pfu Polymerase. 
Reaction Setup (Pfu Polymerase) 
Amount Component 
5 µl Pfu buffer 
5 µl dNTP Mix 
1 µl Pfu polymerase 
1 µl DMSO 
0.5 µl forward primer 
0.5 µl reverse primer 
400 ng template DNA 
ad. 50 µl nuclease free water 
 
Table 3-2: PCR Program for PCR reactions using Pfu Polymerase. 
PCR Program (Pfu Polymerase) 
Phase Step Temperature [°C] Time 
initial denaturation denaturation 95 7 min 
amplification (35 cycles) denaturation 95 40 sec 
annealing 60/65/70 40 sec 
extension 72 2 min per 1 kb 
final extension extension 72 14 min 
hold 4 ∞ 
 
Table 3-3: Reaction Setup for PCR reactions using Phusion Flash Master Mix. 
Phusion Flash Polymerase 
Phase Step Temperature [°C] Time 
initial denaturation denaturation 98 10 sec 
amplification (30 cycles) denaturation 98 1 sec 
annealing 72 5 sec 
extension 72 15 sec per 1 kb 
final extension extension 72 1 min 
hold 4 ∞ 
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Table 3-4: PCR Program for PCR reactions using Phusion Flash Master Mix. 
PCR Program (Phusion Flash Master Mix) 
Phase Step Temperature [°C] Time 
initial denaturation denaturation 98 10 sec 
amplification (30 cycles) denaturation 98 1 sec 
annealing 72 5 sec 
extension 72 15 sec per 1 kb 
final extension extension 72 1 min  
hold 4 ∞ 
 
3.2.1 Colony PCR 
A colony PCR was performed to check if a gene with the correct size was inserted. 
For this, either the sequencing primers of the corresponding plasmid (Table A.2.4-2) 
were used or the primer pairs designed for the PCR construction (Table A.2.4-1). 
The DNA of a picked E. coli colony was used as template. The PCR was performed 
under the following conditions (Table 3-5 and Table 3-6).  
 
Table 3-5: Reaction Setup for PCR reactions using Dream Taq Polymerase. 
Reaction Setup (Dream Taq Polymerase) 
Amount Component 
1.5 µl 10x Dream Taq buffer green 
1.5 µl dNTP mix 
0.075 µl Dream Taq polymerase 
0.75 µl forward primer 
0.75 µl reverse primer 
10.425 µl nuclease free water 
 
Table 3-6: PCR Program for PCR reactions using Dream Taq Polymerase. 
PCR Program (Dream Taq Polymerase) 
Phase Step Temperature [°C] Time 
initial denaturation denaturation 95 3 min 
amplification (35 cycles) denaturation 95 30 sec 
annealing 65 30 sec 
extension 72 1.5 min per 1 kb 
final extension extension 72 5 min 
hold 4 ∞ 
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The results of the PCR were checked by agarose gel electrophoresis. 
 
3.3 Agarose Gel Electrophoresis 
The separation of gene fragments was achieved by agarose gel electrophoresis. A 
1.5% agarose gel was prepared with agarose, TAE buffer and 1 µl SybrSafe for 
visualization of the DNA fragments. The DNA samples were mixed with six volumes 
of loading dye and loaded into the wells. 5 µl of a DNA size marker were also loaded 
as a reference into a separate well. The separation was achieved by running the 
agarose gel in TAE buffer at 120 mV for 30 to 60 min. The visualization was 
performed using VersaDoc, Quantity One Software (4.6.9) and the filter setting SYBR 
Green. 
 
3.4 Restriction Enzyme Analysis 
This method was performed to ensure that ligation and transformation were 
successful. The plasmid was checked using a single cutting enzyme or a double 
cutting enzyme which cuts inside the new ligated gene fragment and creates distinct 
fragment sizes. The digestion was performed as recommended by the enzyme 
supplier (NEB, Thermo Fisher Scientific). The results of the digestion were checked 
by agarose gel electrophoresis and the fragment sizes were compared to the 
calculated sizes. 
 
3.5  Double Digestion 
Double digestion was carried out for sticky end ligation of elongated PCR products 
and the plasmids. The digestion was performed as the enzyme supplier 
recommended with 1 µl enzyme per 1 µg DNA. An agarose gel electrophoresis was 
performed to separate the double digested DNA. The DNA fragments in the size of 
interest were excised and purified. 
 
3.6 Purification of PCR Products and double digested DNA 
Fragments 
The excised gel bands containing PCR products or double digested DNA fragments 
were transferred into 1.5 ml Eppendorf tubes. The purification was performed with 
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the GeneJet Gel Extraction Kit (Thermo Fisher Scientific) as the supplier 
recommended. The DNA was eluted into water. 
 
3.7 Sequencing 
Sequencing of the plasmid constructs was performed by the company Eurofins MWG 
with the respective primers (Table A.2.4-2). The results were analyzed using Clone 
Manager software. 
 
3.8 Computation Tools 
Translation of nucleotide sequences to a protein sequence was performed using the 
ExPASy translate tool (http://web.expasy.org/translate/). Multiple sequence 
alignments were done using the ExPASy ClustalW tool (http://embnet.vital-it.ch/ 
software/ClustalW.html). Box shading multiple sequence alignments was performed 
with the ExPASy BoxShade tool (http://embnet.vital-it.ch/software/BOX_form.html) 
with the following settings: EPS_portrait as output format and other as input 
sequence format. Determination of physical and chemical parameters of a protein 
was done with the ExPASy ProtParam tool (http://web.expasy.org/protparam/) with 
compact as output format. 
 
3.9 Photometric Determination of DNA Concentration 
The DNA concentration of plasmids, purified PCR products and double digested DNA 
fragments was determined photometrically. An absorption of 1 at 260 nm equals a 
concentration of 50 ng/µl. For the quantification 2 µl reference (H20 or elution buffer, 
depending on the eluent of the sample) and 2 µl sample were pipetted on a Take3 
plate of the Eon plate reader (BioTek). The absorbance was measured at 260 nm. 
The purity was determined using the ratio of A260nm/A280nm which should fall between 
1.7 and 1.9. A ratio of lower 1.7 and higher 1.9 indicates a contamination with protein 
or RNA, respectively. 
 
3.10 Ligation 
Ligation was performed to create a circular plasmid containing the gene of interest. 
The ligation solution was 10 µl in total volume and contained 33.3 ng/kb double 
digested DNA, 33.3 ng/kb double digested plasmid DNA, 1 µl T4 DNA ligase and 1 µl 
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T4 DNA ligase buffer. The solution was incubated for one to two hours at room 
temperature and then transformed into E. coli cells. 
 
3.11 Preparation of E. coli Competent Cells 
E. coli competent cells were prepared by inoculating 50 ml LB medium with 500 µl 
overnight culture of the respective E. coli strain. When using E. coli containing a 
plasmid the respective antibiotic was added to the medium. The cells were grown at 
37°C with 180 rpm until an OD600 of ~4. The cells were harvested by centrifugation 
at 4°C and 4500 g for 20 min. The cell pellet was resuspended in 2.5 ml TSS medium 
and 50 µl of this were transferred into precooled 1.5 ml Eppendorf tubes and 
immediately frozen in liquid nitrogen or on dry ice.  
 
3.12 DNA Transformation 
An aliquot of competent E. coli cells was gently thawed on ice for 10 min. 10 µl 
ligation mixture, or 1 µg plasmid DNA or a 1:1 mixture of two different plasmid DNAs 
(only with commercial competent E. coli cells) was given to the cells and incubated 
on ice for 30 min. The cells were heated at 42°C for 45 sec and placed directly back 
on ice for 3 min. 200 µl LB medium were added to the cells containing no antibiotics 
or the suitable antibiotic if competent cells contained a plasmid. The cells were 
incubated for 60 min at 37°C with 220 rpm. After that they were plated on LB agar 
plates containing the appropriate antibiotic or antibiotics. The plates were incubated 
at 37°C overnight. 
 
3.13 Construction of P450 Fusion Enzymes 
For the construction of insect P450-BMR fusion enzymes two plasmids types have 
been generated. i) pASK-IBA33_CYP_BMR_KS (containing a BM3 N-terminus) and 
ii) pASK-IBA33_CYP_BMR_XS (without BM3 N-terminus). 
The construction of the fusion enzymes was started based on the plasmids ordered 
at MWG Eurofins and selected subsequently as modified by A. Baumann, see section 
3.1. A scheme of the construction process is shown in Figure 4-8. E. coli TOP10 cells 
were transformed with the constructed plasmids for amplification and sequencing 
with the respective primers (Table A.2.4-2). After sequence verification the plasmid 
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was purified and E. coli BL21 (expression cells) cells were transformed with the 
plasmid. 
 
3.13.1 Construction of P450 Fusion Enzymes with BM3 N-terminus 
The pASK-IBA33 vectors containing the insect CYP genes with truncated N-termini 
were used as template for PCR. The PCR created a KpnI site at the N-terminal end 
of the gene and a BM3 linker region with a SalI site at the C-terminal end using 
primers shown in Table A.2.4-1. The PCR fragment and the vector pASK-IBA33_BM3 
were double digested with KpnI and SalI creating a ~1500 bp CYP PCR fragment 
and a 5113 bp vector backbone. Ligating the PCR fragment into the vector backbone 
pASK-IBA_BMR resulted in the final plasmid pASK-IBA33_CYP-BMR_KS. This 
created the constructs pASK-IBA33_CYP6A1-BMR_KS, pASK-IBA33_CYP6G1-
BMR_KS, pASK-IBA33_CYP6AE14-BMR_KS, pASK-IBA33_CYP4G1-BMR_KS and 
pASK-IBA33_CYP4G2-BMR_KS. 
 
3.13.2 Construction of P450 Fusion Enzymes without BM3 N-terminus 
Construction of P450 fusion enzymes without a BM3 N-terminus, was carried out as 
described in section 3.13.1 modified by the use of PCR creating an XbaI site at the 
N-terminal site of the CYP gene (Table A.2.4-1). The reverse primers were the same 
as before (Table A.2.4-1).The XbaI-SalI digestion created a ~1530 bp CYP PCR 
fragment and a 4916 bp vector backbone. Ligating the PCR fragment into the vector 
backbone pASK-IBA_BMR resulted in the final plasmid pASK-IBA33_CYP-BMR_XS. 
This created the constructs pASK-IBA33_CYP6A1-BMR_XS, pASK-IBA33_CYP6G1-
BMR_XS, pASK-IBA33_CYP6AE14-BMR_XS, pASK-IBA33_CYP4G1-BMR_XS and 
pASK-IBA33_CYP4G2-BMR_XS. 
 
3.14 Construction of CYP4G fusion enzymes with a short linker 
For the construction of fusion proteins with a shortened (20 amino acids) BM3 linker 
the pASK-IBA33_CYP4G_BMR_XS (without BM3 N-Terminus) constructs were used 
as templates. A schematic representation of the construction is shown in Figure 4-37. 
For the PCR amplification the same XbaI forward primers and newly designed 
reverse primers, which were again creating SalI restriction enzyme sites, were used, 
see Table A.2.4-1. The plasmid pASK-IBA33_BM3 and the PCR products, CYP4G1 
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and CYP4G2, were double digested with XbaI and SalI. The backbone pASK-
IBA33_BMR and the PCR fragments were ligated. By this two plasmids have been 
generated: i) pASK-IBA33_CYP4G1-BMR_shortLinker, ii) pASK-IBA33_CYP4G2-
BMR_shortLinker. After that, E. coli TOP10 cells were transformed with the 
constructed plasmid. E. coli BL21 (DE3) cells were transformed with the plasmid 
after the size of the plasmid was verified by colony PCR and the sequence was 
verified by sequencing with the respective primers (Table A.2.4-2).  
 
3.15 Construction of a CYP4G Fusion Enzyme with a P450 Gene from 
Forficula auricularia  
A schematic representation of the construction of CYP4GForficula-BMR fusion is 
shown in Figure 4-42. For the gene amplification of CYP4G from Forficula auricularia 
ten earwig larvae were frozen in liquid nitrogen and their mRNA was extracted using 
the mRNA gene isolation kit (Roche). Subsequently, the mRNA was transcribed into 
cDNA using the primers listed in Table A.2.4-3, to amplify the ORF of CYP4G by 
PCR on this cDNA pool were designed based on transcriptomic F. auricularia data 
[51] (Table A.2.4-3). The cDNA was used as template for PCR amplification of the 
CYP4GF gene. The PCR product was ligated into the pCR-TOPO blunt vector. The 
PCR on plasmid pCR_CYP4GF using a Pfu proofreading polymerase and primers 
(Table A.2.4-1) that add BsaI restriction sites and a C-terminal His6-tag to the 
amplificate was conducted under the conditions mentioned in section 3.2. The PCR 
product and the vector pASK-IBA33plus were double digested with BsaI, purified and 
ligated to create the vector pASK-IBA33_CYP4GF. For final construction of pASK-
IBA33_CYP4GF_BM3 the vector pASK-IBA33_CYP4GF was used as a PCR 
template. The PCR was performed with a primer pair that creates an N-terminal XbaI 
or KpnI site and a C-terminal SalI site, which does not include the His6-tag (Table 
A.2.4-1). pASK-IBA33_CYP4GF-BMR_XS (without BM3 N-terminus) was generated 
by ligating the XbaI-SalI cut, 1757 bp PCR fragment CYP4GF_XS into the 4916 bp 
vector backbone pASK-IBA33_BMR purified from a XbaI-SalI digestion of pASK-
IBA33_BM3. pASK-IBA33_CYP4GF-BMR_KS (with BM3 N-terminus), was generated 
by ligating the KpnI-SalI cut, 1590 bp PCR fragment CYP4GF_KS into the 5113 bp 
vector backbone pASK-IBA33_BMR purified from a KpnI-SalI digestion of pASK-
IBA33_BM3. After that E. coli TOP10 cells were transformed with the constructed 
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plasmid and the sequence verified. E. coli BL21 cells were transformed with the 
plasmid for protein production. 
 
3.16 Construction of a Duet-Vector with P450 and hCPR Genes 
without Linker 
For the construction of a pET-Duet-1 vector with an insect P450 gene and the hCPR 
gene for coexpression without a linker the construct pCDF-Duet-1_hCPR (which was 
constructed by A. Baumann) and pASK-IBA33_CYP were used. A schematic 
representation of the construction is shown in Figure 4-46. pCDF-Duet-1_hCPR was 
double digested with NdeI, which cuts at the N-terminal site of the gene, and AatI, 
which cuts at the C-terminal site of the gene. The same enzymes were used for the 
double digestion of the pET-Duet-1 vector. The purified fragments were ligated and 
E. coli TOP10 cells were transformed with the constructed plasmid pET-Duet-
1_hCPR. After confirming the sequence via colony PCR and sequencing of the 
plasmid, using the respective primers (Table A.2.4-1) the plasmid was used for 
further construction. The second plasmid pASK-IBA33_CYP was used as a template 
for PCR with a primer pair creating a BamHI site N-terminal and a NotI site C-terminal 
to the gene (Table A.2.4-1). The PCR product and the pET-Duet-1_hCPR plasmid 
were double digested with BamHI and NotI, purified and ligated. E. coli TOP10 cells 
were transformed with the constructed plasmid, pET-Duet-1_CYP_hCPR. E. coli 
BL21 (DE3) cells were transformed with the plasmid whose size was verified by 
colony PCR. 
 
3.17 Overnight Culture 
For overnight cultures 5 ml or 50 ml of LB medium with an appropriate antibiotic were 
inoculated with either a single colony of an LB agar plate or from a cryo-stock. The 
cultures were grown at 37°C for 16 hours. 5 ml cultures were shaken at a speed of 
220 rpm and 50 ml cultures at a speed of 180 rpm. 
 
3.18  Cryo-Stocks 
Cryo-stocks were prepared in order to preserve the plasmid DNA for storage in 
cloning and expression strains of E. coli. For this purpose 500 µl of an overnight 
culture were transferred into a Roti-Store cryo vial (Roth), mixed and incubated for 
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two min. After removing the supernatant from the cryo rings the vials were stored at 
-80°C. 
 
3.19  Plasmid Isolation 
Plasmid isolation was performed with the Quick Lyse Miniprep Kit (Qiagen). Cells of 
4 ml overnight culture were used according to the vendor’s protocol. The plasmid 
DNA was eluted in either 30 µl water, when used for cloning, or elution buffer when 
used for DNA transformation. 
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3.20 Expression 
Expression conditions of proteins like medium, temperature, induction time, flask, 
volume etc. vary depending on the plasmid and the application, see  
Table 3-7. The media were inoculated with fresh 16 h overnight cultures. The gene 
expression on plasmid pASK-IBA33plus was induced with 200 µg/l 
anhydrotetracycline and the gene expression on plasmid pCDFDuet-1 and pETDuet-
1 was induced with 1 mM IPTG. 
Table 3-7: Overview of Expression Conditions. 
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f lask volume [ml] 
 
100 1000 1000 100 100 25 
flask type 
 
plain baffled baffled plain plain GC vial 
medium 
 
TB TB TB M9 TB TB 
medium volume 
[ml] 
 
50 400 800 50 50 5 
total volume per 
construct [ml] 
 
50 2000 2400 50 50 5 
additives 
 
no yes yes yes yes yes 
amount overnight 
culture for 
inoculation [ml] 
 
5 40 80 0.5 5 0.5 
shaking [rpm] 
 
180 180 180 180 180 180/130  
temperature until 
induction [°C] 
 
37 37 37 37 37 37 
induction time  at OD600 
~1  
after 
1.5 h 
after 
1.5 h 
at OD600 
~0.1-0.2 
after 1.5 h after 1.5 h 
temperature 
during expression 
[°C] 
 
37 28 28 37/28 37/28 37 
duration [h] 4 4 4 0-48 4 4 
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3.21  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The separation of denatured proteins by their size was enabled by SDS-PAGE with 
4-15% Mini- PROTEAN TGX gels (Bio-Rad) with 10 or 15 wells. The protein samples 
were mixed with 3x Laemmli buffer to a total volume of 15 µl, heated at 95°C for 
10 min and loaded into the wells. 5 µl of a protein size marker were also loaded as 
a reference into one well. Separation was achieved by running the gel in Rotiphorese 
10x SDS-PAGE buffer at 300 mV for 17 min. Visualization of the proteins was 
achieved by immersing the gel in Roti-Blue quick for at least 30 min. The gel was 
documented using the VersaDoc Quantitiy One Software (4.6.9) with the filter setting 
for Coomassie Blue. 
 
3.22  Western Blot Immunodetection 
Western blot was performed when the protein could not be correctly identified or 
visualized by SDS-PAGE or when degradation of a protein should be determined. 
The proteins separated by SDS-PAGE were electrophoretically transferred to a 
polyvinylidene difluoride (PVDF) membrane by a semi-dry method (Trans-Blot-Turbo, 
Bio-Rad). The membrane was equilibrated for 10 min in methanol. Afterwards the 
membrane, the filter papers and the SDS-PAGE gel were incubated for 15 min in 
SDS-transfer buffer. The protein was transferred for 30 min with 30 mA/cm2. After 
blotting, the membrane was washed twice with TBS buffer for 10 min at room 
temperature. An anti-penta-histidine-antibody (Qiagen) was used, which is directed 
against the His6-oligopeptide, since all proteins were expressed with a terminal His6-
tag. The membrane was incubated for one hour in a blocking solution containing 1% 
casein protein. Then the membrane was washed twice for 10 min with TBS/T buffer 
and once for 10 min with TBS buffer. After this, the membrane was incubated for one 
hour with antibody solution (Anti His HRP, 1:1000 in 0.5% blocking solution) and 
washed again twice with TBS and once with TBS/T for 10 min each. The antibody 
was labelled with peroxidase and was detected by the oxidation of Luminol following 
the manufacturer’s protocol. Chemiluminescence was documented using the 
VersaDoc Quantity One Software (4.6.9) with filter settings Chemie Hi Sensitivity. 
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3.23 Protein Quantification 
3.23.1 BCA-Assay 
The determination of the protein amount was performed with the Thermo Scientific 
Pierce BCA Protein Assay, which is based on the Biuret reaction. In alkaline solution 
proteins form a complex with bivalent copper ions which reduces them to monovalent 
copper ions. The cuprous cations together with bicinchoninic acid (BCA) form a 
purple complex, which can be detected at 562 nm. The microplate assay was carried 
out as described in the manufacturer’s protocol using a bovine serum albumin (BSA) 
standard curve (BSA concentrations ranging from 5-2000 µg/ml). 
 
3.23.2 Photometric Determination of Protein Concentration 
For fast analysis the protein amount was determined using absorption at 280 nm 
(absorption of aromatic amino acid residues). Absorbance coefficients for the fusion 
constructs were determined depending on their amino acid sequence, shown in Table 
3-8. 
 
Table 3-8: Extinction coefficients at 280 nm of proteins. 
Name Extinction coefficient at 280 nm 
CYP6G1-BMR_XS 0.918 
CYP6G1-BMR_KS 0.928 
CYP6A1-BMR_XS 0.966 
CYP6A1-BMR_KS 0.973 
BM3 1 
hRed 1.279 
BMR 1.142 
CYP6G1d22 0.826 
CYP6A1d22 1.008 
Aldehyddecarbonylase 0.834 
Acyl-ACP reductase 0.989 
CYP4G1-BMR 1.037 
CYP4G2-BMR 0.971 
CYP6A1-BMR_shortLinker 0.974 
CYP6G1-BMR_shortLinker 0.925 
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Name Extinction coefficient at 280 nm 
CYP4G1-BMR_shortLinker 1.036 
CYP4G2-BMR_shortLinker 1.034 
CYP4GF-BMR_shortLinker 1.010 
 
The buffer in which the protein was eluted was used as reference. 2 µl reference and 
2 µl sample were pipetted on a Take3 plate and the absorbance was measured at 
280 nm. 
 
3.24 Cell Lysis 
3.24.1 Ultra-Sonic Homogenizer 
For cultures with volumes smaller than 100 ml cell lysis was performed using the 
ultrasonic homogenizer Sonopuls HD2200 with a MS 72 sonotrode (Bandelin). The 
cell lysis was performed on an ice water bath in a rosett cell. The size of the rosett 
cell was chosen depending on the culture volume. Sonication was performed four 
times for one minute at 32% power and 3 times 10% cycles with two min breaks in 
between to prevent overheating of the sample. 
 
3.24.2 Homogenizer 
Cultures with volumes bigger than 100 ml were lysed using the homogenizer M-110P 
(Microfluidics). The interaction chambers of the device were cooled by an ice water 
bath. The sample was passed through the machine twice with 1500 bar and collected 
on ice.  
 
3.25 Protein Purification 
3.25.1 Fusion Protein Purification (at RT) 
3.25.1.1 IMAC via His6-tag (Ni-NTA) 
The cells were resuspended in 200 ml lysis buffer (RT) (pH 7.5, 30 mM Tris-HCl, 
100 mM NaCl, 20% glycerol, proteinase inhibitors, 1% CHAPS was added after cell 
lysis) (Table A.2.7-2) and lysed twice by microfluidization. The lysed cells were 
centrifuged at 75600 g for 30 min at 10°C. The supernatant was filtered through a 
Rotilabo-syringe filter with a pore size of 0.22 µm and loaded on a freshly packed 
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and conditioned 12 ml Ni-NTA column, connected to the SE04 system (ECOM) at 
room temperature with a flow-rate of 1 ml/min. The column was washed with buffer 
A (RT) (pH 7.5, 30 mM Tris-HCl, 100 mM NaCl, 20 % glycerol (v/v), 0.1% CHAPS) 
(Table A.2.7-2) at 3 ml/min until the baseline was reached. The enzyme was eluted 
with 200 mM imidazole at 3 ml/min flow-rate. The purification was monitored using 
two channels with 280 nm and 410 nm. The collection of the fractions of interest was 
started when A280 and A410 started to increase and stopped when the baseline was 
reached. 
 
3.25.1.2 Anion-Exchange Purification (at RT) 
For the anion exchange purification the pooled IMAC fractions were used. After 
dilution (10 fold) in anion exchange buffer A (RT) (pH 7.4, 10 mM NaOH, 20% 
glycerin, 0.1% CHAPS) (Table A.2.7-2) the sample was loaded on a 20 ml DEAE-
Sepharose column at 1 ml/min flow-rate and washed with anion exchange buffer A 
until the baseline was reached. The enzyme was eluted in two steps, first with 
500 mM NaCl at 1 ml/min flow-rate, which eluted the protein of interest and then the 
column was rinsed with 1 M NaCl. Collection of the fractions of interest was started 
when the A280 and A410 started to increase and stopped when the baseline was 
reached. 
 
3.25.2 Fusion Protein Purification 
3.25.2.1 IMAC via His6-tag (Ni-NTA) (at 4°C) 
All steps were performed on ice. The cells were resuspended in 40-60 ml lysis 
buffer 1 (pH 7.5, 30 mM Tris-HCl, 100 mM NaCl, 20% glycerol) (Table A.2.7-3), 
depending on their growth and lysed. The lysed cells were centrifuged at 75600 g for 
1 hour at 10°C. The supernatant was loaded on a freshly packed and conditioned 3 
ml Ni-NTA column, connected to the ÄktaPrime (at 4°C) with 1 ml/min. The column 
was washed with buffer A (pH 7.5, 30 mM Tris-HCl, 100 mM NaCl, 20% glycerol (v/v), 
30 mM imidazole) (Table A.2.7-3) at 3 ml/min flow-rate until the baseline was 
reached. The enzyme was eluted with 250 mM imidazole at 3 ml/min flow-rate. 
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3.25.2.2 Anion-Exchange Purification at (4°C) 
All steps were performed on ice. For the anion exchange purification 3 ml of pooled 
IMAC fractions were used. They were diluted 10 fold in anion exchange buffer A 
(pH 7.4, 20 mM Tris-HCl, 20 % glycerin) (Table A.2.7-3) to a final volume of 30 ml. 
The sample was loaded on a 1 ml DEAE-Sepharose column, connected to the 
ÄktaPrime (at 4°C) at 0.5 ml/min flow-rate and washed with anion exchange buffer A 
(Table A.2.7-3) until the baseline was reached. The enzyme was eluted with 500 mM 
NaCl at 1 ml/min flow-rate. The collection of the fractions of interest was started 
when the A280 started to increase and stopped when the baseline was reached. 
 
3.25.3 hCPR Purification 
3.25.3.1 IMAC via His6-tag (Ni-NTA) 
The cells of 2.4 l culture were resuspended in 200 ml lysis buffer (Table A.2.7-4) and 
lysed twice by microfluidization. The lysed cells were centrifuged at 75600 g for 
60 min at 10°C. When Table A.1.1-1 shows only one centrifugation step the 
supernatant was filtered through a Rotilabo-syringe filter with a pore size of 0.22 µm 
and loaded on a freshly packed and conditioned 10 ml Talon or Ni-NTA column (Table 
A.1.1-1), connected to the SE04 system (ECOM) at room temperature with a flow-
rate of 5 ml/min. If Table A.1.1-1 indicates two centrifugation steps the supernatant 
was discarded and the cells were resuspended in lysis buffer (Table A.2.7-4) and 
lysed by ultrasonication. After centrifugation at 75600 g for 30 min at 10°C the 
supernatant was filtered through a Rotilabo-syringe filter with a pore size of 0.22 µm 
and loaded on 10 ml Ni-NTA column, as described above. The column was washed 
with buffer A (Table A.2.7-4) at 5 ml/min flow-rate until the baseline was reached. 
The enzyme was eluted with 100 mM imidazole at 5 ml/min flow-rate. The purification 
was monitored using three channels with 280 nm. The collection of the fractions of 
interest was started when the A280 started to increase and stopped when the baseline 
was reached. 
 
3.25.3.2 Anion-Exchange Purification 
For the anion exchange purification the pooled IMAC fractions were used. Those 
were diluted in 10 volumes of IMAC buffer A (Table A.2.7-4). The sample was loaded 
on a 3 ml Source Q 15 column at 1 ml/min flow-rate and washed with anion exchange 
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buffer A until the baseline was reached. The enzyme was eluted with an increasing 
NaCl gradient from 0 mM to 500 mM over 20 column volumes, which eluted the 
protein of interest and then the column was rinsed with 1 M NaCl. The collection of 
the fractions of interest was started when A280 started to increase and stopped when 
the baseline was reached. 
 
3.25.4 BM3 Purification 
3.25.4.1 IMAC via His6-tag (Ni-NTA) 
The cells of 2.4 l culture were resuspended in 200 ml lysis buffer and lysed twice by 
microfluidization. The lysed cells were centrifuged at 75600 g for 30 min at 10°C. 
The supernatant was filtered through a Rotilabo-syringe filter with a pore size of 
0.22 µm and loaded on a freshly packed and conditioned 15 ml Ni-NTA column, 
connected to the SE04 system (ECOM) at room temperature with a flow-rate of 
5 ml/min. The column was washed with buffer A (pH 7.5, 30 mM Tris-HCl, 100 mM 
NaCl, 20 % glycerol (v/v)) (Table A.2.7-5) at 5 ml/min flow-rate until the baseline was 
reached. The enzyme was eluted with 100 mM imidazole at 5 ml/min flow-rate. The 
purification was monitored using two channels with 280 nm and 410 nm. The 
collection of the fractions of interest was started when the A280 and A410 started to 
increase and stopped when the baseline was reached. 
 
3.25.4.2 Anion-Exchange Purification 
For the anion exchange purification the pooled IMAC fractions were used. Those 
were diluted in 10 volumes of anion exchange buffer A (pH 7.4, 10 mM NaOH, 20% 
glycerol) (Table A.2.7-5). The sample was loaded on a 5 ml Q Sepharose column at 
5 ml/min flow-rate and washed with anion exchange buffer A (Table A.2.7-5) until the 
baseline was reached. The enzyme was eluted with an increasing NaCl gradient from 
0 mM to 500 mM over 10 min, which eluted the protein of interest and then the column 
was rinsed with 1 M NaCl. The collection of the fractions of interest, was started 
when the A280 and A410 started to increase and stopped when the baseline was 
reached. 
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3.26 Photometric Heme Detection 
A photometric measurement of purified fusion enzyme fractions was performed to 
determine if the heme is still present after purification. The test was performed using 
the photometer (analytic Jena) and 1 ml cuvettes scanning from 300 to 500 nm. 
500 µl of appropriate buffer was used as blank and 500 µl of undiluted elution 
samples were tested afterwards. 
 
3.27 Enzyme Activity Test 
3.27.1 Photometric NADPH Detection 
NADP+ absorbs in UV at 259 nm due to the adenine base, whereas NADPH absorbs 
at 259 nm and 340 nm. This difference allows the detection of a conversion of one 
to the other when monitoring the absorption at 340 nm.  
 
Figure 3-1: Reaction of NADPH to NADP+ catalyzed by P450 reductase. 
This method was used to determine the activity of the reductase domain by 
monitoring the conversion of NADPH to NADP+. The reaction is shown in Figure 3-1. 
It can be used to measure the fusion enzyme activity indirectly by measuring the 
turnover of NADPH by the reductase domain. The electron flow is shown in Figure 
3-2. 
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Figure 3-2: Electron flow from NADPH to reduced P450. 
Equal amounts of NADPH and substrate were used. The 200 µl reaction mixtures 
contained 10 µl/100 µl purified fusion enzyme, 0.1 mM NADPH, 0.1 mM substrate 
and 25 mM Tris-HCl, with 20% glycerin (v/v), pH 7.5. All measurements were run 
with three controls in comparison, without NADPH, without substrate and with 
denatured enzyme using the Eon plate reader (Biotek). The oxidation of NADPH was 
monitored at 340 nm over time with one read per minute. 
 
3.27.2 Photometric Cytochrome c Assay 
The photometric cytochrome c assay was used for the hCPR activity determination. 
Thereby cytochrome c is used as a surrogate substrate for hCPR, which changes its 
color from its oxidized to reduced form. The color change is detectable at 550 nm. 
The assay was performed based on the Nature protocol by Guengerich and 
coworkers [52]. The reaction mixtures contained 40 µM cytochrome c, a determined 
volume of purified hCPR and 300 mM potassium phosphate buffer pH 7.7 added to 
a final volume of 990 µl. The baseline was determined at 550 nm for 3 min. After this 
the reaction was started by adding 100 µM NADPH and measuring for 3 min at 
550 nm. 
 
3.27.3 Photometric pNCA-Assay  
The enzyme activity of BM3 can be tested directly by the photometric pNCA-assay. 
p-nitrophenoxycarboxylic acids (pNCA) can be used as surrogate substrates for BM3. 
The enzyme catalyzes pNCA to yellow p-nitrophenolate, which is detectable at 
410 nm, and the corresponding ω-oxycarboxylic acid [53], see Figure 3-3. 
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Figure 3-3: Enzyme catalysis of pNCA to yellow p-nitrophenolate and the corresponding 
ω- oxycarboxylic acid. 
 
3.28  Lyophilization 
Lyophilization was performed to exchange solvent for GC- or LC-MS analysis. The 
samples containing substrate dissolved in dichlormethane (imidacloprid) or methanol 
(aldrin) were lyophilized in 2 ml Eppendorf tubes in an CHRIST RVC 2-33IR for about 
1.5 hours until all solvent was dissolved. 
 
3.29 Liquid Chromatography Mass Spectrometry (LC-MS) 
3.29.1 In-House Measurements 
Prior to the sample measurements the LC-MS protocol was developed for the analyte 
imidacloprid. For this, the standards were measured using different LC settings and 
analyte concentrations, starting with 1 µg/ml and decreasing. The photometrically 
measured samples were either desalted or mixed 1:2 with acetonitrile for LC-MS 
measurements. For desalting SEP-PAK PlusLight C18 cartridges (Waters) were used. 
They were conditioned with 2 ml methanol followed by 2 ml water. The sample was 
loaded on the cartridge, washed with 3 ml water and eluted in 1 ml methanol. The 
substrates were concentrated by lyophilization and the solvent was exchanged to 
acetonitrile. The substrate and products were determined by LC-MS measurements 
using an Ultimate 3000 (Dionex) equipped with a reversed-phase column (Kinetex 
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2.6 u C18, 100 Å, 150 x 2.1 mm, Phenomenex) connected to an Ion Trap amaZon 
ETD mass spectrometer (Bruker). The HPLC method used water with 0.1% formic 
acid as solvent A and acetonitrile with 0.1% formic acid as solvent B. The method 
lasted 20 min at a flow-rate of 250 µl/min with 20% solvent B at the beginning for 
two min. The solvent B concentration was increased to 90% over 8 min. The concen-
tration was kept for 8 min. The MS program used electrospray ionization with 
alternated polarity with a scan from 80-550 m/z. The ESI nebulizer ran with 1 bar, 
dry gas with 8 l/min and the dry temperature was set to 220°C. 
 
3.29.2 Ultraperformance Liquid Chromatography (UPLC)-MS 
UPLC-MS measurements were performed at the company Chromicent in Berlin 
following the method of Kamel [54]. A LC-MS/MS instrument consisted of a Waters 
UPLC equipped with an AQUITY HSS T3 column (100 x 2.1 mm internal diameter, 
1.8 µm particle size) (Waters) coupled to a Waters Xevo TQ-S micro MS detector. 
The HPLC method used water with 0.1% formic acid as solvent A and acetonitrile as 
solvent B. The method lasted 17 min with a flow-rate of 0.5 ml/min with 95% solvent 
A at the beginning for three min. The solvent B concentration was linearly increased 
to 60% in 12 min. The concentration was held for two min. The injection volume was 
5 µl. The MS operated in the positive electrospray ionization mode. The source 
temperature was set at 120°C with nitrogen flow-rates of 20 l/h for the cone gas and 
1000 l/h for the desolvation gas. The desolvation temperature was 600°C. Prior to 
the measurements standard curves of imidacloprid and imidacloprid-olefin 
(3.125 µg/ml, 6.25 µg/ml, 12.5 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml, 200 µg/ml) were 
measured in triplicates whereby the 200 µg/ml concentrations were excluded since 
they were too high. Imidacloprid and imidacloprid-olefin were quantified by the 
corresponding standard curve. The stocks of the standards were set up in a 10 fold 
concentration in methanol and mixed as shown in Table 3-9. The samples were 
prepared as shown in Table 3-10. 
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Table 3-9: Setup of Imidacloprid and Imidacloprid-Olefin Standards for UPLC-MS 
measurements. 
Setup Standards 
 total volume [µl] 200 
substrate starting concentration final concentration vol [µl] 
tris buffer (pH 7.5) 100 mM 25 mM 50 
imidacloprid 10x standard 1x standard 20 
NADPH 10 mM 0.5 mM 10 
CYP6G1-BMR         100 
water 
  
20 
 
Table 3-10: Setup of enzyme reaction with imidacloprid as substrate for UPLC-MS 
measurements. 
Reaction Setup 
 total volume [µl] 500 
substrate starting concentration final concentration vol [µl] 
tris buffer (pH 7.5) 100 mM 25 mM 125 
imidacloprid 1 mg/ml 100 µg/ml 50 
NADPH 10 mM 0.5 mM 25 
CYP6G1-BMR         160 
water 140 
 
After incubation at room temperature for 25 h the samples were mixed 1:1 with 
acetonitrile and send on ice to the company. 
 
3.30 Gas Chromatography Mass Spectrometry (GC-MS) 
3.30.1 Aldrin and Dieldrin Detection by GC-MS (in-house) 
Substrate and product were determined by GC-MS measurements using an Agilent 
5977 Series GC/MSD System equipped with a HP-5ms Ultra Inert 
(30 m x 250 µm x 0.25 µm) column. From the photometrically measured samples 
(400 µl) aldrin and dieldrin were mixed with 10 µl chlorden (1 mg/ml) as internal 
standard and extracted twice with two times 400 µl methylene chloride. The 
dichloromethane extracts were dried with sodium sulfate and concentrated by 
lyophilization (3.28). The solvent was exchanged to a final volume of 200 µl hexane. 
1 µl of the sample was injected with a splitless injection mode for 1 min. The GC 
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program started with 50°C column oven temperature hold for 2 min, then heated up 
to 300°C with 10°C/min and a final hold for 8 min. The carrier gas was helium with a 
flow-rate of 1 ml/min. The MSD transfer line temperature was 250°C and the MS was 
operated with EI energy of 70 eV and full scan mode with a mass range of m/z 50 to 
400. 
 
3.30.2 Alkane Detection by GC-MS (in house) 
The measurements were performed on a GC-MS CT 1128 (Constellation Technology 
Corporation) equipped with a VF-5MS column (30 m x 0.25 mm internal diameter, 
0.25 µm film thickness, Agilent Technologies). The injector and transfer line 
temperatures were 230°C and 260°C, respectively. The GC method was established 
by analyzing an alkane standard (C8-C20) (4 µg/µl) which was added to an E. coli 
culture. 25 mg pellets of expression cultures were mixed with ethyl acetate and 
sonicated for 5 min at 33% power (3.24.1). After this the mixture was centrifuged at 
14000 g for 20 min at 4°C. The supernatant was transferred into a glass vial and 
analyzed by GC-MS. The method was 26 min long and started at 70°C oven 
temperature. The temperature increased linear to 300°C at a rate of 10°C per minute.  
 
3.30.3 Alkane Detection by GC-MS (Schmallenberg) 
For sample preparation expression cultures from 400 ml and 800 ml TB medium or 
50 ml and 400 ml M9 medium were harvested. For the analysis 140 mg pellet of the 
M9 cultures or 220 mg pellet of TB cultures were mixed with 1 ml ethyl acetate. The 
mixtures were sonicated on ice for 3 min at 20% power with a MS 72 sonotrode in a 
glass centrifuge tube (3.24.1). Subsequently, the samples were centrifuged for 1 min 
at 4500 rpm and 4°C. The supernatants were transferred with a glass pipette into a 
glass vial. 5 ml of the supernatant of the expression cultures were mixed with 2.5 ml 
ethyl acetate. The samples were sonicated in the ultrasonic water bath for 3 min. 
After this the samples were centrifuged for 1 min at 4500 rpm and 4°C. The 
supernatants were transferred with a glass pipette into a glass vial. 
For the GC-MS detection an Agilent Technologies 5973 equipped with a Rxi-5HT 
column (30 m x 0.25 mm internal diameter, 0.25 µm film thickness) (Restek) was 
used. The program started at 50°C which was held for 4 min. The temperature 
increased linearly to 300°C at a rate of 20°C/min. The temperature was held for 
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25 min. After this the temperature increased to a final temperature of 350°C at a rate 
of 15°C/min. The temperature was held for 3 min. The helium carrier gas ran at a 
flow-rate of 1.2 ml/min. The MS source temperature was 250°C and the MS quad 
temperature 180°C. 
 
3.30.4 Solid-Phase Microextraction (SPME)-GC-MS 
The detection of aldehydes and alkanes in coexpression cultures was performed with 
SPME-GC-MS. Analytes were enriched at 37°C for 30 min on a SPME fiber (Supelco 
polydimethylsiloxane, 100 µm thickness) exposed to the headspace of a 5 ml sample 
of a 4 h expression culture in a 20 ml glass vial. The analysis was performed using 
an Agilent 5977 Series GC/MSD System equipped with a HP-5ms Ultra Inert (30 m x 
250 µm x 0.25 µm) column. The SPME desorption was performed for 1 min in the GC 
injector in a splitless injection mode. The GC injector temperature was 250°C and 
the SPME fiber was conditioned under helium in an independent injector port for 
5 min at 250°C. The GC-MS method is the same as for aldrin detection using GC-
MS (in-house) (3.30.1) 
 
3.30.5 SPME Measurements with added Aldehyde (no Coexpression) 
The detection of produced alkanes in single-expression cultures was performed with 
SPME-GC-MS. The substrate octadecanal (1 µg/µl) or a C8-C20 aldehyde (4 ng/µl) 
mixture were added (10 µl or 100 µl respectively) to the expression system at t0 of 
the protein production. The enrichment and measurements were performed as 
described in 3.30.4. 
 
3.31 Photometric Heme Substrate Binding Test 
The binding of a substrate at the heme binding domain of a P450 enzyme leads to a 
peak absorption shift from its former maximum towards higher wavelength, 
depending on the P450. The test was performed at a photometer (analytic Jena) 
using 1 ml cuvettes. The baseline was determined using 400 µl of the appropriate 
buffer plus 40 µl DMSO (solvent of the substrate). The first measurement from 300 
to 500 nm was performed with 400 µl of an undiluted elution sample of CYP6G1-
BMR, or denatured CYP6G-BMR and 40 µl DMSO. After this measurement 400 µl of 
the same samples were mixed with 40 µl 1 mg/ml imidacloprid in DMSO and 
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measured from 300 nm to 500 nm. The different measurements were compared to 
see if the peak shifts from 425 nm to another wavelength. 
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4 Results and Discussion 
4.1 Purification Approach 
To establish the “Molecular Lego” system for insect P450s the following approach 
was performed. First the insects P450s had to be selected. The selection was based 
on the P450s origin, the sequence availability and their potential substrates should 
be known to enable activity measurements (Table 4-1). 
 
Table 4-1: Overview of selected insect P450s for this study. 
P450 Origin Substrates GenBank 
CYP6A1 Musca domestica heptachlor, aldrin [55] M25367.1 
CYP6G1 Drosophila melanogaster 
imidacloprid, DDT, 
methoxychlor [56] 
AAF58557.1
CYP6AE14 Helicoverpa armigera 
(gene expression is 
induced by) gossypol [57] 
DQ986461.1
CYP4G1 Drosophila melanogaster 
C24 C26 and C28 
aldehydes [30] 
Q9V3S0.1 
CYP4G2 Drosophila melanogaster octadecanal [30]  EF615002.1 
 
The aim was to design and construct a variable insect P450-BMR fusion where the 
insect P450 can be swapped and produced in E. coli and purified without the addition 
of detergents. E. coli was chosen as expression host since it is well described and 
often used for the expression of soluble proteins. To be sure that the building blocks 
can be produced active in E. coli pretests were performed to determine the best 
conditions (A.1). 
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4.2 Construction of Insect P450 Fusion Enzymes 
4.2.1 Genetic Analysis of CYP6A1, CYP6G1, CYP6AE14, CYP4G1, 
CYP4G2 
The multiple sequence alignments of all used insect P450s are shown in Figure 4-1 
and Figure 4-2. Within the CYP6 family the CYP6AE14 does have more differences 
towards CYP6A1 and CYP6G1 than CYP6A1 to CYP6G1. The sequence difference 
is reflected by their catalytic reactions. CYP6A1 and CYP6G1 both oxidize 
insecticides, aldrin and imidacloprid, respectively [55-56]. CYP6AE14, on the other 
hand, is predicted to have gossypol as substrate [57]. The size, shape and amino acid 
composition of the enzyme binding pocket determines the substrate specificity [58]. 
The substrates molecule size is an important factor for the substrate specificity. This 
can be seen here for the selected enzymes and their substrates. Gossypol has a 
molar mass of 518.563 g/mol, which is bigger than aldrin with a molar mass of 
364.91 g/mol and imidacloprid with a molar mass of 255.66 g/mol. 
 
CYP6A1       1 MDFGSFLLYALGVLASLALYFVRWNFGYWKRRGIPHEEPHLVMGNVKGLRSKYHIG--EIIADYYRKFKGSGPFAGIFLG 
CYP6G1       1 MVLTEVLFVVVAALVALYTWFQRN-HSYWQRKGIPYIPPTPIIGNTKVVFKMENSFGMHLSEIYNDPRLKDEAVVGIYSM 
CYP6AE14     1 -MITSLLLTAVFVIIFTIYLVSKKKYQYWEKRKVPHLPPVPLLGNFGNFILQRQFLGYTLQQICG--KFPNVPYVGAYFG 
 
CYP6A1      79 HKPAAVVLDKELRKRVLIKDFSNFANRGLYYNEKDDPLTG-HLVMVEGEKWRSLRTKLSPTFTAGKMKYMYNTVLEVGQR 
CYP6G1      80 NKPGLIIRDIELIKSILIKDFNRFHNRYARCDPHGDPLGYNNLFFVRDAHWKGIRTKLTPVFTSGKVKQMYTLMQEIGKD 
CYP6AE14    78 TEPALIVQDPEHIKLVMTKDFYFFSSREISEYADRERFTQN-LFSTSGNKWKVLRQNLTPVFTSAKMKNMFHLIEKCSHV 
 
CYP6A1     158 LLEVMYEKLEVSS---ELDMRDILARFNTDVIGSVAFGIECNSLRNP-HDRFLAMGRKSIEVPRHNALIMAFIDSFPELS 
CYP6G1     160 LELALQRRGEKNSGSFITEIKEICAQFSTDSIATIAFGIRANSLENP-NAEFRNYGRKMFTFTVARAKDFFVAFFLPKLV 
CYP6AE14   157 FEDFLDKEAKSN----EVEMRALVARYTMDCIGTCAFGVETKTMNVTENNPFTAVGNSIFMLSRVQGFKFVLRGIYPSLF 
 
CYP6A1     234 RKLGMRVLPEDVHQFFMSSIKETVDYREKNNIRRNDFLDLVLDLKNNPESI-----------SKLGGLTFN--ELAAQVF 
CYP6G1     239 SLMRIQFFTADFSHFMRSTIGHVMEERERSGLLRNDLIDVLVSLRKEAAAE-----------PSKPHYAKNQDFLVAQAG 
CYP6AE14   233 YLLGFRTLPPEVNAFFSNLMTGVFKGRNYTPTSRNDFVDFVLKWKQNKTMTGDSLTNMKYDSQKKVTLEVDDDLLVAQCF 
 
CYP6A1     301 VFFLGGFETSSSTMGFALYELAQNQQLQDRLREEVNEVFDQFKEDNISYDALMNIPYLDQVLNETLRKYPVGSALTRQTL 
CYP6G1     308 VFFTAGFETSSSTMSFALYEMAKHPEMQKRLRDEINEALVEGG-GSLSYEKIQSLEYLAMVVDEVLRMYPVLPFLDREYE 
CYP6AE14   313 IFFAAGYETSATTLSFTLYELAKHPEAQKRAIAEVDDYLRRHN-NELKYECLSEMPFVEACFDETLRKYPVLSLLTREVV 
 
CYP6A1     381 NDYVVPHN-----PKYVLPKGTLVFIPVLGIHYDPELYPNPEEFDPERFSPEMVKQRDSVDWLGFGDGPRNCIGMRFGKM 
CYP6G1     387 SVEGQPDLSLKPFYDYTLENGTPVFIPIYALHHDPKYWTNPSQFDPERFSPANRKNIVAMAYQPFGSGPHNCIGSRIGLL 
CYP6AE14   392 EDYTFPSG-------LKVEKGLRIFLPLYHLHHNPEFFPDPEEYRPERFLPENKDKIKPYTYMPFGEGPRLCIGMRFAKM 
 
CYP6A1     456 QSRLGLALVIRHFRFTVCSRTDIPMQINPESLAWTPKNNLYLNVQAIRKKIK---------- 
CYP6G1     467 QSKLGLVSLLKNHSVRNCEATMKDMKFDPKGFVLQADGGIHLEIVNDRLYDQSAPSLQ---- 
CYP6AE14   465 QMTAGIITLLKKYRLELAPGMPQNIEFEPNSFVSQVAGGINLKMIKRESWEGRLLKNLEKAY 
 
Figure 4-1: Multiple sequence alignment of the family CYP6 P450s (CYP6A1, CYP6G1 and 
CYP6AE14) used in this study. Black and gray shading represent amino acid identity and 
similarity, respectively.  
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The members of subfamily CYP4G show very high sequence similarities (Figure 4-2). 
Similar catalytic activities have also been demonstrated for CYP4G1 and CYP4G2, 
they both use long-chain aldehydes as substrates and catalyze them to long-chain 
alkanes. 
 
CYP4G1      1 MAVEVVQETLQQAASSSSTTVLGFSPMLTTLVGTLVAMALYEYWRRNSREYRMVANIPSPPELPILGQAHVAAGLSNAEI 
CYP4G2      1 ---------MDSANNSTAGPATVLNPIWTALLGIAVVVSLYEIWLRNTRKYKLTANMPNPPMLPLIGNGHLVAHLTNAEI 
 
CYP4G1     81 LAVGLGYLNKYGETMKAWLGNVLLVFLTNPSDIELILSGHQHLTKAEEYRYFKPWFGDGLLISNGHHWRHHRKMIAPTFH 
CYP4G2     72 LARGIGYMQTYGGAMRGFLGPMLVVFLWNAPDIELILSTHTHLEKSIEYRFFKPWFGDGLLISNGHHWQHHRKMIAPTFH 
 
CYP4G1    161 QSILKSFVPTFVDHSKAVVARMGLEAGKSFDVHDYMSQTTVDILLSTAMGVKKLPEGNKSFEYAQAVVDMCDIIHKRQVK 
CYP4G2    152 QSILKSFVPAFVQHSKKVVERMAKELGKEFDVHDYMSQTTVEILLSTAMGVKKVPEDNKSLEYAKAVVDMCDIIHKRQLK 
 
CYP4G1    241 LLYRLDSIYKFTKLREKGDRMMNIILGMTSKVVKDRKENFQEESRAIVEEIS-TPVASTPASKKEGLRDDLDDIDENDVG 
CYP4G2    232 FFYRMDALYNLSSMSEKGKKMMDIILGMTRKVVTERQQNFNAESRAIVEEDDEISKQKQQAKKKEGLRDDLDDIDENDVG 
 
CYP4G1    320 AKRRLALLDAMVEMAKNPDIEWNEKDIMDEVNTIMFEGHDTTSAGSSFALCMMGIHKDIQAKVFAEQKAIFGDNMLRDCT 
CYP4G2    312 AKKRLALLDAMMAMSKNPDVEWTDKDVMDEVNTIMFEGHDTTSAGSSFVLCMLGIYKDIQEKVLAEQKAIFGDNFLRDCT 
 
CYP4G1    400 FADTMEMKYLERVILETLRLYPPVPLIARRLDYDLKLASGPYTVPKGTTVIVLQYCVHRRPDIYPNPTKFDPDNFLPERM 
CYP4G2    392 FADTMEMKYLERVIMETLRLYPPVPLIARRAEFDVKLASGPYTIPKGTTVVIAQFAVHRNPQYFPNPEKFDPDNFLPERM 
 
CYP4G1    480 ANRHYYSFIPFSAGPRSCVGRKYAMLKLKVLLSTIVRNYIVHSTDTEADFKLQADIILKLENGFNVSLEKRQYATVAGG- 
CYP4G2    472 ANRHYYSFIPFSAGPRSCVGRKYAMLKLKVLLSTIIRNYSVQSNQQEKDFKLQADIILKIENGFNIMLNRRPEAMKAMGG 
 
Figure 4-2: Sequence alignment of the subfamily 4G P450s (CYP4G1 and CYP4G2) used in 
this study. Black and gray shading represent amino acid identity and similarity, respectively.  
As representatives of the two families CYP6G1 and CYP4G1 from the same 
organism, Drosophila melanogaster, were aligned to identify similarities (Figure 4-3). 
The amino acid sequence EXXR (yellow) and CXG (blue) are conserved in P450s. 
Otherwise both sequences do not show many similarities, which is typical for the 
different P450 families with their broad range of substrates [59]. 
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CYP6G1    1 ------------------------MVLTEVLFVVVAALVALYTWFQRNHSYWQRKGIPYIPPTPIIGNTKVVFKMENSFG 
CYP4G1    1 MAVEVVQETLQQAASSSSTTVLGFSPMLTTLVGTLVAMALYEYWRRNSREYRMVANIPSPPELPILGQAHVAAGLSNAEI 
 
CYP6G1   57 MHLSEIYNDPRLKDEAVVGIYSMNKPGLIIRDIELIKSILIKDFNRFHNRYARCDPHGDPLGYNNLFFVRDAHWKGIRTK 
CYP4G1   81 LAVGLGYLNKYGETMKAWLGNVLLVFLTNPSDIELILSG------HQHLTKAEEYRYFKPWFGDGLLISNGHHWRHHRKM 
 
CYP6G1  137 LTPVFTSGKVKQMYTLMQEIGKDLELALQRRGEKNSGSFITEIKEICAQFSTDSIATIAFGIRANSLENPNAEFRNYGRK 
CYP4G1  155 IAPTFHQSILKSFVPTFVDH---SKAVVARMGLEAGKSFD--VHDYMSQTTVDILLSTAMGVKKLPEGNKSFEYAQAVVD 
 
CYP6G1  217 MFTFTVARAKDFFVAFFLPKLVSLMR-----------------IQFFTADFSHFMRSTIGHVME----------ERERSG 
CYP4G1  230 MCDIIHKRQVKLLYRLDSIYKFTKLREKGDRMMNIILGMTSKVVKDRKENFQEESRAIVEEISTPVASTPASKKEGLRDD 
 
CYP6G1  270 LLRNDLIDVLVS----LRKEAAAEPSKPHYAKNQDFLVAQAGVFFTAGFETSSSTMSFALYEMAKHPEMQKRLRDEINEA 
CYP4G1  310 LDDIDENDVGAKRRLALLDAMVEMAKNPDIEWNEKDIMDEVNTIMFEGHDTTSAGSSFALCMMGIHKDIQAKVFAEQKAI 
 
CYP6G1  346 LVEGGG-SLSYEKIQSLEYLAMVVDEVLRMYPVLPFLDREYESVEGQPDLSLKPFYDYTLENGTPVFIPIYALHHDPKYW 
CYP4G1  390 FGDNMLRDCTFADTMEMKYLERVILETLRLYPPVPLIARRLDYDLKLASG------PYTVPKGTTVIVLQYCVHRRPDIY 
 
CYP6G1  425 TNPSQFDPERFSPANRKNIVAMAYQPFGSGPHNCIGSRIGLLQSKLGLVSLLKNHSVRNCEATMKDMKFDPKGFVLQADG 
CYP4G1  464 PNPTKFDPDNFLPERMANRHYYSFIPFSAGPRSCVGRKYAMLKLKVLLSTIVRNYIVHSTDTEADFKLQADIILKLENGF 
 
CYP6G1  505 GIHLEIVNDRLYDQSAPSLQ 
CYP4G1  544 NVSLEKRQYATVAGG----- 
 
Figure 4-3: Sequence alignment of the representatives (CYP6A1 and CYP4G1) of each P450 
family (CYP6 and CYP4). Black and gray shading represent amino acid identity and 
similarity, respectively. The conserved amino acid patterns EXXR (yellow) and CXG (blue) 
are characteristic for P450s. 
 
4.2.2 Construction of Insect P450 Fusion Enzymes based on the 
Natural Fusion Enzyme BM3 
Eukaryotic P450s and their P450 reductases are dependent on each other and 
membrane bound. This makes them difficult to produce recombinantly, but there are 
bacterial P450 enzymes, which do not have a membrane anchor and thus are easier 
to produce recombinant. A remarkable bacterial enzyme is the enzyme CYP102A1 
(BM3) from Bacillus megaterium. The enzyme is not membrane bound and 
furthermore a natural fusion enzyme. It contains three domains, the N-terminal P450 
(BM3-P450), a linker and the C-terminal reductase (BMR) (Figure 4-4) which makes 
it a self-sufficient fusion enzyme, which is independent of further enzymes.  
 
 
Figure 4-4: Schematic representation of the three domain structure of BM3. 
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The construction of P450 fusion enzymes based on BM3 shall overcome the 
disadvantages of eukaryotic P450s described above. This approach will enable the 
soluble recombinant production, purification and activity measurements of insect 
P450s.  
Our approach is following the “Molecular Lego” principle constructed by Gilardi for 
membrane bound human P450s [23]. Following this principle the P450 domain of the 
BM3 will be replaced by an insect P450, which leads to a construct of a C-terminal 
insect P450 attached to the BM3 linker and N-terminal BMR domain (Figure 4-5).  
 
 
Figure 4-5: Schematic representation of starting genes and final fusion constructs.  Starting 
genes: insect P450 and BM3, including the util ized restriction enzyme sites XbaI, KpnI and 
SalI. Final fusion constructs: insectP450-BMR without BM3 N-Terminus and insectP450-
BMR with BM3 N-Terminus. 
To enable better solubility of our fusion construct the N-terminus of the insect P450, 
which contains the membrane anchor domain, was truncated by approximately 20 
amino acids. In the process it is important not to truncate too much, otherwise the 
P450 activity is decreased, the study showed that the amino acid residues 21-82 of 
the human CYP2E1 are crucial for heme incorporation and correct heme pocket 
folding [60]. The N-terminus should not include hydrophobic amino acids and the exact 
amount was determined based on human P450 studies used for fusion enzyme 
construction [23]. Figure 4-6 and Figure 4-7 show the N-terminus of the constructs 
with the selected positions, highlighted in green, where the N-terminus is truncated. 
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CYP6A1      1 MDFGSFLLYALGVLASLALYFVR/WNFGYWKRRGIPHEEPHLVMGNVKGLRSKYHIG--EIIADYYRKFKGSGPFAGI-//- 
CYP6G1      1 MVLTEVLFVVVAALVALYTWFQR/N-HSYWQRKGIPYIPPTPIIGNTKVVFKMENSFGMHLSEIYNDPRLKDEAVVGI-//- 
CYP6AE14    1 –MITSLLLTAVFVIIFTIYLVS/KKKYQYWEKRKVPHLPPVPLLGNFGNFILQRQFLGYTLQQICG--KFPNVPYVGA-//- 
 
Figure 4-6: Sequence alignment of the N-termini of CYP6A1, CYP6G1 and CYP6AE14. / 
indicates the determined start of the N-terminally truncated P450. . -//- indicates that the 
sequence is not shown in complete length. 
CYP4G1      1 MAVEVVQETLQQAASSSSTTVLGFSPMLTTLVGTLVAMALYEYWRRNSREYR/MVANIPSPPELPILGQAHVAAGLSN-//- 
CYP4G2      1 ---------MDSANNSTAGPATVLNPIWTALLGIAVVVSLYEIWLRNTRKYKLTAN/MPNPPMLPLIGNGHLVAHLTN-//- 
 
Figure 4-7: Sequence alignment of the N-termini of CYP4G1 and CYP4G2. / indicates the 
determined start of the N-terminally truncated P450. -//- indicates that the sequence is not 
shown in complete length. 
To further optimize the solubility of the designed fusion enzymes a construction setup 
was established, which contains 52 amino acids of the BM3 N-terminus in front of 
the insect CYP N-terminus (Figure 4-8 A) which will be called KS. To compare if this 
yields to a higher solubility an additional construction setup without a BM3 N-
terminus was created (Figure 4-8 B). The construction of those two different fusion 
enzymes was achieved by using either the KpnI or the XbaI cloning site. The KpnI 
site is located 156 base pairs downstream the N-terminus of the BM3 P450 domain. 
Using this site will create a construct with a BM3 N-terminus. Using the XbaI cloning 
site, which is located on the vector backbone 42 base pairs upstream of the BM3 N-
terminus, will create the construct without the BM3 N-terminus. The construction of 
both fusion enzymes is based on the same starting plasmids and shown in Figure 
4-8. 
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Figure 4-8: Schematic representation of insect P450-BMR fusion enzyme construction. A: 
Construct CYP-BMR_KS, B: Construct CYP-BMR_XS 
 
The linker length is very important for the fusion enzyme activity since it determines 
the interaction of the BMR domain and the P450 domain, thus allowing electron flow 
from BMR to the catalytic center of the P450 domain [61-63]. A BM3 linker reduced by 
six amino acids inactivates the fusion enzyme by inhibiting the domain 
interaction [46]. Therefore, we chose a linker length of 29 amino acids. An overview 
of all constructs generated by this method is listed below in Table 4-2. 
 
 
 
 
 
 
Results and Discussion 
 
 
46 
 
Table 4-2: Overview of constructed fusion proteins. 
P450 Origin Cloning 
Sites 
Name Fusion Protein Abbreviation 
CYP6A1 
Musca 
domestica 
KpnI, SalI 
pASK-IBA33_ 
CYP6A1_BM3_KS 
CYP6A1-BMR_KS 
XbaI, SalI 
pASK-IBA33_ 
CYP6A1_BM3_XS 
CYP6A1-BMR_XS 
CYP6G1 
Drosophila 
melanogaster 
KpnI, SalI 
pASK-IBA33_ 
CYP6G1_BM3_KS 
CYP6G1-BMR_KS 
XbaI, SalI 
pASK-IBA33_ 
CYP6G1_BM3_XS 
CYP6G1-BMR_XS 
CYP6AE14 
Helicoverpa 
armigera 
KpnI, SalI 
pASK-IBA33_ 
CYP6AE14_BM3_KS 
CYP6AE14-BMR_KS 
XbaI, SalI 
pASK-IBA33_ 
CYP6AE14_BM3_XS 
CYP6AE14-BMR_XS 
CYP4G1 
Drosophila 
melanogaster 
KpnI, SalI 
pASK-IBA33_ 
CYP4G1_BM3_KS 
CYP4G1-BMR_KS 
XbaI, SalI 
pASK-IBA33_ 
CYP4G1_BM3_XS 
CYP4G1-BMR_XS 
CYP4G2 
Drosophila 
melanogaster 
KpnI, SalI 
pASK-IBA33_ 
CYP4G1_BM3_KS 
CYP4G2-BMR_KS 
XbaI, SalI 
pASK-IBA33_ 
CYP4G1_BM3_XS 
CYP4G2-BMR_XS 
 
4.2.3 Discussion of the Construction of Insect P450 Fusion Enzymes 
P450s are present in various forms in all insect species investigated in this regard. 
The knowledge about them is limited since it is difficult to produce them as 
heterologous proteins [1 ]. Gilardi and coworkers were able to show by the “Molecular 
Lego” approach the possibility of soluble expression of membrane bound human 
P450s [49,  64]. They showed that the construct, P450 2E1-BMR with 21 amino acid 
reduced N-terminus, was active and that this method can be transferred to other 
human P450s [23]. The goal of this study was to the transfer the approach to insect 
P450s. For the soluble expression of insect P450s in E. coli, insect P450s were 
combined with the BMR domain of BM3, which was not yet shown. The selection of 
the insect P450s was based on the availability of their sequences and the knowledge 
of their potential substrates (Table 4-1). CYP6A1, CYP6G1 and CYP6AE14 are 
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members of the xenobiotic metabolism and able to hydroxylate their substrates 
[57,  65- 66]. CYP4G1 and CYP4G2 are able to decarbonylate aldehydes and thus part 
of the insect defense, reproduction and communication [30]. E. coli was selected as 
expression organism because it was described best for the production of human 
P450 fusion enzymes constructed by the “Molecular Lego” method [23,  60]. 
Furthermore, it was characterized best for soluble protein production [67], which is 
necessary for the direct activity detection. Usually the vector pCW ori+ is used for 
the expression of P450s in bacteria. For this work the vector pASK-IBA33plus was 
selected since it showed good soluble expression of other insect enzymes in 
E. coli [68-69].To enable higher solubility the N-terminal domain of the P450s was 
truncated. By this the hydrophobic amino acids were discarded which usually bind to 
the membrane. Further solubility should be achieved by creating constructs which 
have a BM3 N-Terminus domain in front of the optimized P450 [60]. This created the 
constructs called KS. As comparison fusion enzymes without a BM3 N-terminus, 
called XS, were created. The construction was achieved by restriction enzyme 
cloning. The following chapters of this thesis shall verify if the constructs are 
expressed soluble and can be purified without detergents and if their activity can be 
determined. 
 
4.3 Production and Purification of Human Reductase and BM3 
To determine the best expression conditions for vector pASK-IBA33plus in E. coli 
BL21 we performed several tests. Each test consisted of separate expressions of the 
human P450 reductase (hCPR) with a truncated N-terminus and the BM3 enzyme 
under different conditions (Table A.1.1-1). The results of the tests are shown in 
appendix (A.1) and were important for the determination of protein production and 
purification conditions of the fusion enzyme constructs. The enzyme activity 
measurements (A.1.3 and A.1.4) show that the basic building blocks of the fusion 
enzymes are produced active. 
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4.4 Protein Production and Purification of Insect P450 Fusion 
Enzymes 
4.4.1 Overexpression of Insect P450 Fusion Enzymes in E. coli 
The overexpression of the insect P450 fusion enzymes for subsequent IMAC 
purifications was performed based on the knowledge obtained at the preliminary 
expression tests of hCPR and BM3 (A.1). The expression was performed in TB 
medium with 1 mM 5-aminolevulinic acid, 1 mM thiamin, 2µM riboflavin, 0,5 mg/l 
FeCl3 and 80/160 mM D(+)-glucose. The δ-aminolevulinic acid and thiamine are 
important for the build-up of the heme ring in the P450 domain and glucose shall 
support the stability of the reductase domain. Protein production was triggered by 
anhydrotetracycline once E. coli cells reached an OD600 of 0.5. Cells were grown at 
37°C for 4.5 h and harvested by centrifugation prior lyses. 
The constructs based on CYP6AE14 did not show good overexpression yields 
compared to the CYP6A1 and CYP6G1 constructs. Furthermore, the first purification 
trials did not show any good results. Therefore, we performed all further expression 
and purification modifications only with the constructs based on CYP6A1 and 
CYP6G1. 
 
4.4.2 Purification of Insect P450 Fusion Enzymes 
4.4.2.1 Purification without Detergents at Room Temperature 
The cells were treated as described previously (A.1.2). The supernatant was loaded 
on a fresh, equilibrated 15 ml Ni-NTA column. The target protein CYP6A1-BMR was 
eluted with 200 mM imidazole. 
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Figure 4-9: Purification of CYP6A1-BMR. Elution profile of the IMAC purification of CYP6A1-
BMR.  
 
Figure 4-10: SDS-PAGE analysis of sample preparation for IMAC purification and IMAC 
purified CYP6A1-BMR fractions. A: 1-2: t0 pellet and supernatant, 3-4: t4.5h pellet and 
supernatant, 6-7: pellet and supernatant after microfluidization, 7: supernatant after 
centrifugation, 8: after fi l tration B: E4-E10: elution fractions, FT: flow through. 
The theoretical molecular weight of the construct CYP6A1-BMR is 121.36 kDa. We 
did not observe any overexpression in expected size, see Figure 4-10 A well 3 and 
4 (indicated by scattered line), and purification did not show satisfactory results, see 
Figure 4-10 B. This is why we had to modify the approach. The first try was to purify 
the IMAC samples further by anion exchange purification. The fractions E5-E10 of 
the IMAC purification were pooled and diluted in ten volumes of anion exchange 
buffer A (Table A.2.7-2) to enable binding of the protein on a freshly-conditioned 
10 ml DEAE-Sepharose anion exchange column. 
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Figure 4-11: SDS-PAGE analysis of the elution fractions E10-E15 of the anion exchange 
purification of CYP6A1-BMR. M: marker. The scattered line indicates the height of the 
expected protein size. 
This approach was performed with the constructs CYP6G1-BMR as well. CYP6G1-
BMR yielded similar results based on SDS-PAGE to the ones shown above from 
CYP6A1-BMR. The two different constructs, which are based on a single CYP6, KS 
and XS, show similar results (not shown). For this reason the following experiments 
were still performed with both constructs. 
 
4.4.2.2 Purification with Detergents at Room Temperature 
The anion exchange purification did not lead to any further purification of the target 
protein. This is why we established new purification approach using CHAPS in the 
buffers (Table A.2.7-2). Apart from that the cells were treated as before (A.1.2) and 
the supernatant was loaded on a freshly-equilibrated 12 ml Ni-NTA column. The 
target protein was eluted with 200 mM imidazole. 
To remove the imidazole an anion exchange purification was performed. The 
fractions E3-E8 of the IMAC purification were pooled and diluted in ten volumes of 
anion exchange buffer A (0.1% CHAPS) (Table A.2.7-2) to enable binding of the 
protein on a fresh, conditioned 10 ml DEAE-Sepharose anion exchange column. The 
chromatogram of the purification using CHAPS as detergent show a single elution 
peak of the protein of interest, indicated by the 410 nm absorption peak, Figure 4-12. 
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Figure 4-12: Purification of CYP6A1-BMR with CHAPS. Elution profile of the anion exchange 
purification of CYP6A1-BMR on a DEAE-Sepharose column with buffers containing 0.1% 
CHAPS. 
 
Figure 4-13: Western blot analysis of IMAC and anion exchange purifications of CYP6A1-
BMR with or without CHAPS. -: without CHAPS, +: with CHAPS, white scattered line: 
fragment size of BMR, red scattered line: size of complete CYP6A1-BMR A: 1: t4.5h pellet, 
2: supernatant after sonication, 3: supernatant after centrifugation, 4: supernatant after 
fi ltration, 5: t4.5h pellet, 6: supernatant after sonication, 7: supernatant after centrifugation, 
8: supernatant B: I5, I6, I10: IMAC fractions 5, 6, 10, A4, A5, A12, A13: anion exchange 
fractions 4, 5, 12, 13. 
The Western blot gels show a comparison of the CYP6A1-BMR samples from before 
(Figure 4-10 and Figure 4-11) and samples from the new approach using CHAPS. 
The samples which do not contain CHAPS (Figure 4-13 A+B, white scattered line) 
show more protein in the size of the BMR domain than the targeted CYP6A1-BMR 
fusion enzyme. The BMR domain is detectable by Western blot since it contains the 
His6-tag at the N-terminus. The samples of the purification preparation containing 
CHAPS (Figure 4-13 A, red scattered line) show almost only the full fusion protein, 
but the purified fractions (Figure 4-13 B, red scattered line) show the fusion protein 
and its degraded products. 
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4.4.2.3 Final Purification Method without Detergents at 4°C 
To enable purification of the complete fusion protein without the use of detergents a 
new expression and purification approach was tested. For this the expression 
temperature was changed to 28°C to enable better production of soluble protein. 
Furthermore, buffers without detergents (Table A.2.7-3) were used and the whole 
procedure was performed on ice or at cooled devices. The purification was performed 
as described in section 3.25.2.1. The elution profile (Figure 4-14 A) of the CYP6A1-
BMR_XS construct shows a single elution peak when eluting with 250 mM imidazole. 
 
Figure 4-14: Purification of CYP6G1-BMR and CYP6A1-BMR without detergent at 4°C with 
250 mM imidazole as eluent. A: Elution profile of the IMAC purification of CYP6G1-BMR and 
CYP6A1-BMR. B: SDS-PAGE analysis of the IMAC purified CYP6G1-BMR. P: pellet after 
sonication and ultracentrifugation, S: supernatant after sonication and ultracentrifugation, 
1-10: elution fractions. A single dominant band corresponding to the 120 kDa CYP6G1-BMR 
is seen in lanes 1-10. 
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The SDS-PAGE (Figure 4-14 B) shows that the fusion protein is purified and 
unimpaired which was not the case in the former purifications (Figure 4-13). The 
IMAC purification yielded a protein concentration of 400 µg/ml. To remove the 
imidazole an anion exchange purification was performed. The pooled fractions were 
diluted in 10 volumes of anion exchange buffer (Table A.2.7-3) to enable binding on 
the DEAE-Sepharose column. A fresh, conditioned 1 ml DEAE-Sepharose anion 
exchange column was used for anion exchange purification. The diluted protein was 
loaded on the column with a flow-rate of 0.5 ml/min to enable protein binding. The 
protein was eluted with sodium chloride. The anion exchange elution profile of 
CYP6A1-BMR_XS (Figure 4-15 A) shows a major elution peak at approximately 9 min 
and a smaller elution peak at approximately 11 min. Only the fractions of the major 
peak were analyzed further. 
 
Figure 4-15: Purification of CYP6A1-BMR without detergents at 4°C. A: Elution profile of the 
anion exchange purification of CYP6A1-BMR. B: SDS-PAGE analysis of the anion 
exchanged purified CYP6G1-BMR. M: marker, FT: flow-through, 1-8: elution fractions. A 
single dominant band corresponding to the 120 kDa CYP6G1-BMR is seen in lanes 4-8. 
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The SDS-PAGE of the anion exchange purification (Figure 4-15 B) shows as well the 
fusion protein at its estimated weight. A high purity was reached but only lower 
concentrations of 300 µg/ml were reached. The purification of CYP6G1-BMR_XS 
show similar results (not shown), but the constructs with the BM3 N-terminus, 
CYP6A1-BMR_KS and CYP6G1-BMR_KS, show lower amounts of purified protein. 
Since the activity of the constructs shall be detected with several methods, a higher 
protein yield is a big advantage. For this reason the following activity measurements 
were performed with the constructs without a BM3 N-terminus. 
 
4.4.3 CYP6-BMR BMR Domain Activity 
It was not shown before if the cooperative function between the fused domains is 
possible. To assess whether the BMR domain is correctly folded and fully functional 
the catalytic activity of the BMR was tested by detection of NADPH consumption. 
The activity was measured in the presence of aldrin (substrate for CYP6A1 [70]), and 
imidacloprid (substrate for CYP6G1 [56]), respectively. The assays were performed 
for 12 h with measurements every minute. Denatured proteins were used as negative 
control. Figure 4-16 shows the results of IMAC purified CYP6A1-BMR_XS. The 
relative activity of 100%, determined by NADPH consumption, was reached by 
CYP6A1-BMR as well as the setup without substrate. The negative control with 
denatured CYP6A1-BMR shows on the contrary only a residual relative activity of 
less than 20%. 
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Figure 4-16: BMR activity assay. NADPH turnover of IMAC purified CYP6A1-BMR with aldrin 
as substrate and of the controls denatured CYP6A1-BMR, no substrate and no NADPH. 
 
 
Figure 4-17: BMR activity assay. NADPH turnover of IMAC and anion exchange purified 
CYP6G1-BMR with imidacloprid as substrate and of the controls denatured CYP6G1-BMR, 
no substrate and no NADPH. 
The measurements with purified CYP6G1-BMR_XS show similar results (Figure 
4-17) as the ones with CYP6A1-BMR_XS (Figure 4-16), the lower activity is based 
on the lower enzyme concentrations used. Additionally, the measurements were 
performed with anion exchanged purified CYP6G1-BMR_XS. Clear differences 
between the IMAC and anion exchange samples can be seen (Figure 4-17). The 
turnover rate of the anion exchange purified sample is only half of the turnover rate 
of the IMAC purified, except for the negative control with denatured enzyme. 
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4.4.4 Discussion of Protein Production and Purification of Fusion 
Enzymes 
The verification of the soluble expression and purification without detergents of the 
insect P450-BMR constructs is described in this chapter. E. coli BL21 cells were 
used as expression system in 400 ml TB cultures with added supplements. The 
parameter evaluation of the expression and purification process lead to stable, 
purified insect P450 fusion enzymes. The best results were achieved when 
expressing at 28°C for 4 h and purification was performed at 4°C without the use of 
detergents. The expression at 28°C caused a lower protein production rate with the 
effect of more soluble produced protein [67]. This is an important factor for the 
purification. Furthermore, the reduction of the temperature during the purification 
from room temperature to 4°C allowed the stable purification of the fusion proteins 
without detergents. CYP6A1 was the first purified insect P450. The protein was 
expressed in E. coli and 50% of it were associated with the membrane fraction [26]. 
The soluble, purified protein was used for direct electrochemistry, which avoids the 
construction of a fusion protein [71-72]. E. coli produced and purified CYP6G1 was 
shown for the first time in 2013 by Cheesman et al.. A two-step purification for the 
removal of formerly used detergents was necessary [28]. The protein expression and 
purification of CYP6AE14 was not shown before. Former studies only focused on the 
detection of its upregulation due to xenobiotic and gossypol treatment [57], this lead 
to the use of RNAi mediated crop protection against the cotton bollworm [73-75]. The 
stable produced proteins CYP6A1-BMR and CYP6G1-BMR allowed further 
experiments. BMR activity could be determined fast photometrically and was 
performed after each purification to verify if further activity measurements by GC- or 
LC-MS were useful. The assay was developed and used to ensure that the redox 
domain was functional and not inhibited by any of the used reagents. The high 
activity in the no substrate control can be explained with the independent activity of 
the BMR domain. Govindaraj and Poulos showed that the BMR domain can be 
produced recombinant active without the P450 domain [48]. This is why the presence 
of the P450 substrate is not necessary for the BMR activity determination, but it was 
still added to exclude inhibiting factors for the BMR activity. The KS constructs 
showed lower protein yields after expression and purification, especially for the 
CYP6G1 construct. Furthermore the KS constructs showed lower NADPH turnover 
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than the XS constructs. Those were the reasons to only proceed further with the XS 
constructs. 
As initial conclusion it can be said that the soluble expression in E. coli and 
purification of insect P450-BMR fusion enzymes is possible and that the solubility 
was increased in comparison to the unmodified insect P450s (Figure 4-18).  
 
Figure 4-18: SDS-PAGE of IMAC purified protein. A: CYP6G1-BMR B: CYP6G1. 
All following experiments were performed with the XS constructs, since they showed 
the better protein yields and the subsequent activity tests were performed 
immediately after purification to avoid impairment of the protein. 
 
4.5 GC-MS Measurements of Aldrin Conversion to determine 
CYP6A1-BMR activity 
4.5.1 Establishment of GC-MS method 
The activity of the P450 domain and a good cooperative function between the fused 
domains of the fusion construct CYP6A1-BMR can be determined by the turnover 
rate of the CYP6A1 substrate aldrin to dieldrin, Figure 4-19 [26]. 
 
Figure 4-19: Reaction from aldrin to dieldrin catalyzed by CYP6A1. 
Activity tests of the fusion construct CYP6A1-BMR were performed in two different 
setups. The first approach included activity assays of purified enzyme in buffer. For 
the setup a method for aldrin and dieldrin extraction and a GC-MS method had to be 
established. Prior to the activity measurements extraction tests without enzyme were 
performed. The sample volume (100 µl, 200 µl or 500 µl) had to be determined. It 
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should contain enough enzyme for the conversion of a detectable amount of 
substrate but also allow the setup of all controls from a single enzyme purification. 
Furthermore, the volume had to be big enough for phase removal with standard pipet 
tips. The extraction parameters had to be evaluated since the published protocol was 
developed for big scale extraction from water samples (http://www.atsdr.cdc.gov/ 
toxprofiles/index.asp, PB2003-100134). The final extraction parameters were that 
500 µl dichloromethane containing 10 µl chlorden internal standard (IS) (1 mg/ml) 
were added to 500 µl incubated sample, because the lower volumes interfered with 
the phase extraction. Chlorden was selected as IS based on chromatographic 
behavior and extraction efficiency, which should be similar to the substrates. To test 
different extraction procedures the upper (aqueous) or lower (dichloromethane) 
phase was removed and the aqueous phase was re-extracted with an additional 
500 µl dichloromethane. The organic phases were pooled and lyophilized until all 
solvent was evaporated. The sample was dissolved in 250 µl hexane.  
 
Figure 4-20: Test extraction of aldrin at t0 and after 43.5 h using dichloromethane. The 
relative peak area is based on the IS peak area. n=3. 
The results (Figure 4-20) show that there is no difference whether to transfer the 
supernatant or lower phase of the dichloromethane-sample-mixture. The measured 
amount of aldrin at t0 in ion exchange buffer is smaller than the amount in IMAC 
buffer. Whether the ion exchange or IMAC buffer were used the amount of recovered 
aldrin shrank by incubation time. A significant difference was detected for the 
different points of time. No significant differences were detected for the upper and 
bottom phase extraction. The significance was determined using ANOVA single 
factor test.  
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4.5.2 Final GC-MS Method and Results 
For the activity measurements of purified CYP6A1-BMR 500 µl samples (30 µg/ml or 
100 µg/ml CYP6A1-BMR, 100 µg/ml aldrin, 0.5 mM NADPH) were incubated at room 
temperature for 0 min, 30 min, 1 h, 4 h, 24 h and 43.5 h. After the incubation the 
substrates were extracted using the method described in (3.30.1).  
 
 
Figure 4-21: GC-MS measurement of IMAC purified CY6A1-BMR incubated with aldrin as 
substrate at room temperature followed by extraction. The relative peak area is based on 
the IS peak area. n=3 
The same measurement was performed with anion purified CYP6A1-BMR to 
eliminate imidazole as an inhibiting factor. 
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Figure 4-22: GC-MS measurement of ion exchanged CY6A1-BMR incubated with aldrin as 
substrate at room temperature followed by extraction. The relative peak area is based on 
the IS peak area. n=3 
The results for aldrin/IS show similar patterns in IMAC and anion exchange purified 
enzyme incubation, with a drastic decrease of aldrin after 1 h (Figure 4-21 and Figure 
4-22). If the amount of aldrin that is lost after 1 h is turned into dieldrin the amount 
of dieldrin should increase after 1 h. However, the dieldrin/IS results show a similar 
pattern as the aldrin/IS results, but with lower values. The observed pattern do not 
show enzyme activity, but rather a non-enzymatic degradation over time of 
incubation. The variation of the dieldrin amount, which is found in the aldrin standard 
itself, can be based on measurement inaccuracy due to the low concentrations of 
dieldrin. 
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To find the reason for the missing CYP6A1-BMR activity the following parameters of 
the experimental setup were changed. To enable better substrate-enzyme-
interaction the enzyme concentration was increased and aldrin was dissolved in 
DMSO instead of methanol. DMSO is a bipolar solvent which should increase the 
solubility in the buffer system and support the aldrin-enzyme contact. 
 
Figure 4-23: GC-MS measurements of IMAC purified CY6A1-BMR incubated with aldrin as 
substrate at room temperature for 1 h followed by extraction. The relative peak area is based 
on the IS peak area. n=3 
Figure 4-23 shows similar results for all measured experimental variations. Aldrin is 
the most abundant analyte with a relative peak area of approximately 0.95 in all 
cases except the control without aldrin. Dieldrin has only a relative peak area of 0.05 
in all cases except the non-aldrin control. This shows that the exchange of substrate 
solvent from methanol to DMSO and the increasing of enzyme concentration from 
30 µg/ml to 100 µg/ml does not yield in higher dieldrin concentrations. 
 
4.5.3 Discussion of GC-MS Measurements of Aldrin Conversion to 
determine CYP6A1-BMR Activity 
This chapter shows the establishment of a GC-MS detection method including an 
extraction protocol for aldrin and the product dieldrin from enzyme incubation 
samples. The extraction protocol was established based on the test extraction of 
aldrin without enzyme. This lead to the conclusion that it is not important, which of 
the phases was transferred first, and that the total assay volume had to be at least 
500 µl to assure good phase separation. Furthermore, the pretest showed that aldrin 
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is not stable in buffer at room temperature for 48 h. For this reason the activity of 
the CYP6A1-BMR construct was measured at different points of time. The 
measurements showed a similar concentration pattern for aldrin and dieldrin but with 
lower concentrations of dieldrin. This shows that no CYP6A1-BMR activity is 
measured only aldrin reduction over time, which was already shown in the performed 
pretests. A possible reason for the inactivity could be the solvent of the substrate. 
For this reason methanol was exchanged to DMSO which should enhance the 
solubility of aldrin in the assay mixture and support the substrate enzyme interaction 
[76-77]. An incubation time of 1 h was selected to exclude the aldrin degradation as 
far as possible, but give the enzyme time to react. It was shown by Andersen and 
coworkers that 0.015-0.065 nmol of CYP6A1 can catalyze aldrin with turnover rates 
of turnover rates of 12 min -1 at 30 °C [26]. The measurements with DMSO showed the 
same results as before, no CYP6A1-BMR activity. Another reason for the missing 
activity could be the P450 itself, that it was not produced correctly folded. This can 
be further evaluated by replacing the CYP6A1 with CYP6G1 which has imidacloprid 
as substrate, which shows different substrate properties than aldrin.  
 
4.6 LC-MS Measurements of Imidacloprid Conversion to determine 
CYP6G1-BMR Activity 
4.6.1 Establishment of LC-MS/MS Method 
The activity of the P450 domain and a good cooperative function between the fused 
domains of the fusion construct CYP6G1-BMR can be determined by the turnover 
rate of the CYP6G1 substrate imidacloprid to 4-hydroxy-, 5-hydroxy-imidacloprid or 
4,5-dihydroxy-imidacloprid [66] shown in Figure 4-24. 
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Figure 4-24: Schematic reaction of CYP6G1 catalyzed imidacloprid to its various products. 
Figure modified from Joußen et al. [66 ]. 
Activity tests of the fusion construct CYP6G1-BMR were performed in two different 
setups. Both approaches included simultaneous NADPH activity assays of purified 
enzyme in buffer. The first tested setup included desalting of the buffer-enzyme-
system before LC-MS measurements whereas the second setup needed no desalting 
before LC-MS measurement. Methods are described in 3.29.1.  
Prior the activity measurements a LC-MS method had to be established and the 
process parameters had to be evaluated to maximize sensitivity for detection of 
imidacloprid and its derivatives. A major drawback for the method establishment was 
that the products 4- and 5-hydroxy-imidacloprid were not commercially available as 
standards. To establish a method for imidacloprid detection imidacloprid was injected 
in different concentrations directly into the MS. This showed us that we would need 
Results and Discussion 
 
 
65 
 
a minimum concentration 250 ng/ml per sample to receive a good signal. Other 
settings that had to be determined were the column, the corresponding HPLC method 
and the sample preparation. To receive the best sensitivity the sample preparation 
was tested in two different setups. The first sample preparation included a desalting 
step. Buffer samples were loaded on a C18 cartridge, washed and eluted with 
methanol. A disadvantage of this method is that it was not possible to determine if 
the reaction product got lost during this procedure since 4- and 5-hydroxy-
imidacloprid were not available as standards. For the second sample preparation 
method the samples were mixed 1:1 (v:v) with acetonitrile. This mixture was loaded 
on the HPLC column and the flow through of salt components was discarded before 
the components of interest were transferred to the MS. This was the most promising 
method since the loss of analytes was prevented by loading of the complete sample 
on the HPLC column. The final LC-MS settings are shown in (3.29.1). The preliminary 
measurements with samples of purified CYP6G1-BMR did not show detectable 
hydroxylated products. It is possible that the sensitivity of the LC-MS was not high 
enough to detect the small traces of the products 4- and 5-hydroxy-imidacloprid. 
Therefore, measurements were performed at Chromicent on a UPLC-MS/MS based 
on the published protocol from Kamil [54]. 
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4.6.2 Results of UPLC-MS/MS Measurements 
Prior to the UPLC-MS/MS measurement the purified enzymes were detected 
photometrically at 340 nm to determine their ability of NADPH oxidation. The 
measurements were performed as described in (3.27.1). 
 
Figure 4-25: Photometric detection of NADPH consumption over time. 
The results in Figure 4-25 show that 100% of NADPH were consumed after 11 h by 
the IMAC purified enzyme at the presence and absence of imidacloprid. The negative 
control with denatured enzyme shows in both cases a turnover of about 20%. The 
anion exchanged purified samples show a weaker activity, the turnover was, with or 
without imidacloprid present, only about 45%. Based on these results one would 
expect the best enzyme activity in the IMAC purified samples. After determination of 
the reductase domain activity the activity of the complete fusion construct was 
determined using UPLC-MS/MS. This method was selected to analyze the samples, 
since it is more sensitive than the LC-MS used before.  
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Figure 4-26: Results of UPLC-MS/MS measurements detecting products hydroxy-
imidacloprid, dihydroxy-imidacloprid and imidacloprid-olefin. n=3 
The results of the UPLC-MS/MS measurements, shown in Figure 4-26, show very 
small peak areas, which are below the detection limit. The results are similar to the 
results of the CYP6A1-BMR construct. The detected imidacloprid-olefin is most likely 
a contamination of the substrate imidacloprid, since it is present in all samples at 
the same level. The amounts of dihydroxy-imidacloprid are at the detection limit. 
Hydroxy-imidacloprid, is the most prominent product in the incubated samples. 
Nevertheless, the total amounts of hydroxy-imidacloprid cannot account for the 
amount of imidacloprid that was reduced in the incubation, see Figure 4-27, which 
were about 1 million counts. 
 
Figure 4-27: Results of UPLC-MS/MS measurements detecting substrate imidacloprid. n=3 
Further investigation of the missing CYP6A1-BMR and CYP6G1-BMR activity lead to 
repetition of the IMAC purification for validation of heme presence. The ÄktaPrime 
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used for the former purifications at 4°C was replaced by the SE04 system (ECOM), 
which is able to detect four different wavelength at the same time. It is capable to 
detect the presence of the heme group with detection at 410 nm at the same time as 
detecting the protein at 280 nm. This way we could make sure that the heme is 
present at the time of purification.  
 
Figure 4-28: Purification of CYP6A1-BMR and CYP6G1-BMR without detergent at 4°C with 
250 mM imidazole as eluent using SE04 system. Elution profile of the IMAC purif ication of 
CYP6A1-BMR and CYP6G1-BMR. 
 
The ratio of the peaks (410 nm: 280 nm) in this purification (Figure 4-28) of 1:10 
corresponds to the former purification (Figure 4-12). To verify the heme presence in 
the fractions they were checked for their heme absorbance peak at 420 nm 
afterwards (Figure 4-29). The measurements from 300 nm to 500 nm were performed 
in a 1 ml cuvette in photometer with the appropriate buffer mix as blank. 
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Figure 4-29: Absorbance spectrum of purified BM3-CYP6A1 and BM3-CYP6G1 from 380 nm 
to 600 nm. The peak at 420 nm indicates the presence of the heme group in the P450 
domain. 
The heme peak at 420 nm is well detectable for the CYP6G1-BMR construct, but not 
for the CYP6A1-BMR construct. 
 
4.6.3 Photometric Heme Substrate Binding Test 
To determine if the substrate is able to bind to the catalytic heme domain of the 
purified fusion enzyme construct a photometric heme substrate binding test was 
performed as described in section 3.31. The test could only be performed with 
purified CYP6G1-BMR since only for this the heme is detectable photometrically as 
seen in Figure 4-29.  
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Figure 4-30: Photometric heme substrate binding test with IMAC purified CYP6G1-BMR and 
imidacloprid as substrate. 
The test did not show any heme peak shift when adding the substrate imidacloprid 
compared to the negative control with DMSO, Figure 4-30. 
 
4.6.4 Discussion of LC-MS Measurements of Imidacloprid Conversion 
to determine CYP6G1-BMR Activity 
Imidacloprid can be catalyzed into three different products, 4-hydroxy-imidacloprid, 
5-hydroxy-imidacloprid, and 4,5-dihydroxy-imidacloprid by CYP6G1, Figure 4-24. 
Furthermore 4- and 5-hydroxy-imidacloprid can be converted to imidacloprid-
olefin [66]. Based on this knowledge the enzyme activity determination of the CY6G1-
BMR construct was performed. Using imidacloprid as substrate the BMR activity of 
the fusion construct CYP6-BMR was shown with the photometric NADPH reduction 
activity assay. The primary aim of the work in this chapter was the activity 
determination of CYP6G1-BMR by detection of the products using LC-MS methods. 
To enable the substrate detection by LC-MS a suitable method and sample 
preparation had to be established. For the in-house LC-MS measurements the 
following two preparation methods were evaluated. First a desalting method using 
C18 cartridges was tested. This method showed the following drawbacks. At first the 
product could be lost due to the necessary working steps. Furthermore, the method 
could not be evaluated with the expected hydroxy-imidacloprid products, since they 
were not commercially available. Due to those reasons the first method was excluded 
and the direct injection approach was selected. This approach involves the addition 
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of the same volume of solvent to the sample and direct measurement. Using the in-
house LC-MS detection no traces of the possible products were detected suggesting, 
that the turnover rate of the CYP6G1-BMR might be very low. Thus the small amounts 
of products could not be detected by our in-house LC-MS method with a detection 
limit of 250 ng/ml. This lead to the decision to measure the samples using the 
published protocol from Kamel on an UPLC-MS/MS at Chromicent GmbH which has 
a lower detection limit [54]. Due to the costs of external measurements only selected 
samples were measured. The results showed a reduction of imidacloprid but the low 
formation of products does not correlate to this. The imidacloprid concentration was 
reduced about 1 million counts compared to the control with denatured protein. On 
the other hand only 50 to 60 counts of 4- and 5-hydroxy-imidacloprid were measured. 
A former study showed that 83% of 400 µg imidacloprid were converted in 48 h by 
CYP6G1 expressed in tobacco cells, 6 l culture, into 58% 4-hydroxy-imidacloprid, 
19% 5-hydroxy-imidacloprid and 6% imidacloprid-olefin [66]. Transferred to our 
samples this would mean that approximately 14.3 µg imidacloprid would have been 
converted and 8.29 µg 4-hydroxy-imidacloprid, 2.72 µg 5-hydroxy-imidacloprid and 
0.86 µg imidacloprid-olefin should have been produced. Those values should be 
detectable using the UPLC-MS/MS approach. Since CYP6G1-BMR activity was not 
detected the remaining controls were not measured.  
In order to determine a possible reason for the missing CYP6G1-BMR and CYP6A1-
BMR activity the constructs were produced recombinant once more for the 
verification of the presence of the heme group in the constructs. During purification 
heme was present in both constructs. After the purification heme presence could 
only be detected in the CYP6G1-BMR construct. This explains the absence of 
CYP6A1-BMR activity since it does not contain a catalytic center after purification. 
The heme might have not been bound properly to the enzyme and got detached due 
to protein instability after purification due to the temperature change from 4°C to 
room temperature during the photometric measurement [78]. The construct CYP6G1-
BMR does have a catalytic center after purification, but its activity is missing as well. 
To determine the reason for the lack of activity, the heme substrate interaction was 
investigated. Heme shows a specific absorbance spectrum with an absorbance 
maximum at 420 nm, when no substrate is bound. This was detected during the 
purification and the subsequent photometric measurement. The absorbance 
maximum changes to higher wave length when the heme binds the substrate [13]. This 
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effect was the basis for the heme substrate photometric assay. The construct 
CYP6G1-BMR did not show any change in the absorbance peak after addition of 
imidacloprid. The missing heme substrate interaction could be explained by a poor 
accessibility of the substrate binding site which prevents the formation of a 
catalytically productive binding mode [79]. This effect might be caused by one of the 
purification steps, which was investigated in the whole-cell section of the thesis.   
 
4.7 Whole-cell Approach 
As shown in the purification approach part of the results and discussion section the 
production and purification of the constructed insect P450-BMR fusions is working 
very well, but the activity of those constructs cannot be shown. To eliminate the 
purification process as a possible reason for the missing activity a whole cell 
approach was established. The selection of P450s was based on their ability to 
produce long-chain alkanes from long-chain aldehydes, which is not a typical P450 
reaction [31]. To achieve a complete whole cell setup the long-chain aldehydes should 
not be added but produced in E. coli by the recombinant acyl-ACP reductase which 
is catalyzing the production of long-chain aldehydes from E. coli ’s naturally produced 
long-chain fatty acids. The whole reaction is shown in Figure 4-31. The plasmid 
constructs in the E. coli coexpression setup is shown in Figure 4-32. 
 
CYPRred           CYPRox 
NADPH         NADP+
NADPH         NADP+
CYP4G
n n nO
O O
H
 
Figure 4-31: Reaction from long-chain fatty acids to long-chain alkanes. Reaction of long-
chain fatty acids to long-chain aldehydes catalyzed by reductase. Follow up reaction of long-
chain aldehydes catalyzed to long-chain alkanes by P450 of the group CYP4G. 
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Figure 4-32: Schematic representation of the coexpression for alkane production in E. coli. 
Acyl-ACP reductase on a pCDFDuet-1 plasmid and the CYP4G-BMR fusion construct on a 
pASK-IBA33plus plasmid in E. coli. 
 
4.8 Construction of Alkane producing E. coli as Positive Control with 
Aldehyde Decarbonylase and Acyl-ACP Reductase from Nostoc 
punctiforme 
The genes with an added His6-tag were synthesized, E. coli K12 codon optimized 
and cloned into their appropriate vector by MWG Eurofins. The vectors, pASK-
IBA33plus and pCDFDuet-1, were selected based on their compatibility for 
coexpression, they are using tac and T7 promoters, respectively, and include 
ampicillin and streptomycin resistance, respectively. The construction is described 
in 3.1 and resulted in the plasmids pCDFDuet-1_AcylACPRed and pCDF-Duet-
1_AcylACPRed. To achieve co-transformed E. coli BL21 (DE3) cells, E. coli had to 
be transformed with pCDF-Duet-1_AcylACPRed first, then made chemically 
competent and then be co-transformed with pASK-IBA33_Alddec. This is described 
in section 3.11 and 3.12. This lead to E. coli BL21 (DE3) cells containing both 
plasmids as shown in Figure 4-37. 
 
 
Figure 4-33: Schematic representation of the coexpression positive control. Acyl-ACP 
reductase on a pCDFDuet-1 plasmid and the aldehyde decarbonylase on a pASK-IBA33plus 
plasmid in E. coli. 
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4.9 Parameter evaluation for GC-MS Alkane Detection 
The GC-MS method parameter evaluation was performed with the alkane standard 
C8-C20 and afterwards with the positive control E. coli BL21 (DE3) with coproduced 
acyl-ACP reductase and aldehyde decarbonylase. The evaluation of parameters for 
protein production was as well performed with the positive control. Following this the 
CYP4G-BMR constructs were measured and evaluated. 
 
4.9.1 GC-MS-Method parameter evaluation  
The first measurements were performed on a GC-MS CT1128 (Constellation 
Technology Corporation) equipped with a VF-5MS column (30 m x 0.25 mm internal 
diameter, 0.25 µm film thickness (Agilent Technologies)). Three initial column oven 
temperatures (50°C, 70°C, 100°C) were tested. From the initial temperature the 
temperature increased at a rate of 20°C/min over two ramps up to 300°C, see 3.30.2. 
The best results were achieved by using an initial temperature of 70°C. This method 
was then used for the evaluation of sample preparation and for further evaluations 
of protein production. The second, more detailed analysis of the samples was 
performed at Fraunhofer IME for applied ecology, Schmallenberg, on a GC-MS 5973 
from Agilent Technologies equipped with a Rxi-5HT column (30 m x 0.25 µm internal 
diameter, 0.25 µm film thickness). The method for this GC-MS was based on the final 
method but had to be adjusted for this instrument. The method started with an initial 
temperature of 50°C increased at 20°C/min up to 300°C with a 25 min hold and a 
second ramp at 15°C/min to final temperature of 350°C, see 3.30.3. 
 
4.9.2 Extraction and Protein Production 
To evaluate the extraction and the protein production for best possible GC-MS data 
several parameters were tested, see Table 4-3 for extraction parameters and Table 
4-4 for protein production parameters.  
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Table 4-3: Overview of changed parameters for evaluation of extraction for GC-MS 
measurement of alkanes. 
Variable 1 2 3 4 5 6 final 
solvent 
Metha-
nol 
Ethyl 
acetate 
Hexane 
Ethyl  
acetate 
Hexane/ 
Dichloro- 
methane 
Ethyl acetate 
ultra-
sonication 
30 min 10 min 5 min no 3 min 3 min 
centrifugation 3 min, 
13000 g 
30 min, 14000 g 
20 min, 
14000 g 
10 min, 4500 g 10 min, 4500 g 
lab ware plastic glass glass 
cell weight 
normalization 
no 220 mg/ml 220 mg/ml 
internal 
standard 
no Octadecane Octadecane 
 
For the final extraction parameters ethyl acetate was selected as solvent, since it 
dissolved alkanes best with this extraction method out of E. coli positive control cells. 
The time of ultra-sonication was reduced to 3 min to avoid evaporation of substances. 
The centrifugation speed had to be reduced to 4500 g based on the glass vials that 
were used. Glass ware was used to reduce the amount of contamination peaks that 
appeared, because plastic components were dissolved by the solvent and detected 
by GC-MS. The cell weight normalization was performed to enable better comparison 
between the different samples. The internal standard octadecane was selected since 
it was no expected alkane produced by one of the constructs and to enable better 
comparison [30]. The evaluation of the protein production was performed 
simultaneously to the extraction evaluation, since some parameters influence each 
other, for example the usage of M9 minimal medium. M9 medium reduced the 
background of the GC-MS measurements drastically, but it had the disadvantage of 
lower growth speed and protein production. To see at which point in time of protein 
production the alkane yield is highest several measurements were taken after 
specific time periods as seen in Table 4-4. 
 
Results and Discussion 
 
 
77 
 
Table 4-4: Overview of changed parameters for evaluation of protein production for GC-MS 
measurement of alkanes. 
Variable 1 2 3 4 5 6 final 
medium TB M9 M9/TB M9 
volume 50 ml 
400 
ml 
800 
ml 
400 ml 50 ml 
inoculation 
volume of 
overnight culture 
5 ml 500 µl 4 ml 
4.5 
ml 
4 ml 500 µl 
duration protein 
production 
4 h 48 h
8 h, 
42 h, 
7 d 
42 h 48 h
4 h, 6 h, 
24 h, 48 
h 
t0, 2 h, 4 h, 
16 h, 24 h, 
42 h 
 
 
Figure 4-34: Coexpression of acyl-ACP reductase and aldehyde decarbonylase. SDS-PAGE 
(A) and Western blot analysis (B) of the in E. coli BL21 (DE3) coexpressed acyl-ACP 
reductase and aldehyde decarbonylase. The acyl-ACP reductase shows a band at the 
expected size of 35 kDa and the aldehyde decarbonylase with its expected size at 70 kDa. 
Figure 4-34 shows the coexpression of acyl-ACP reductase and aldehyde 
decarbonylase. For the final protein production settings M9 minimal medium was 
selected since it immensely reduced the background peaks. The selection of minimal 
medium defined the inoculation volume, since as little LB medium should be 
transferred to the main culture as necessary. The culture volume allowed a higher 
sample size which determined the amount of time point samples.  
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4.9.3 GC-MS-Method (SPME) 
To reduce the matrix effect from the sample medium and to eliminate the requirement 
of sample extraction a SPME-GC-MS-method was established. By this the full 
spectrum of volatile products can be detected. Another advantage of this method is 
that cells can be grown in TB medium with their regular growth and expression rate, 
since the salt content of TB is beneficial for the analysis because of a reduced 
solubility. The establishment of this method was performed using the alkane standard 
(C8-C20) in culture medium to find the correct sampling time. In Figure 4-35 an 
overlay of total ion chromatogram (TIC), extracted ion chromatogram (EIC) 57 and 
EIC 71 of the alkane standard in TB medium and glucose is shown. The masses 57 
and 71 were selected for the EIC based on the typical fragmentation pattern of 
alkanes. 
Results and Discussion 
 
 
79 
 
 
Figure 4-35: SPME-GC-MS measurement of alkane standard in TB + glucose medium and 
30 min sampling time at 37°C. A: TIC, B: EIC m/z 57, C: EIC m/z 71. 1: decane, 2: undecane, 
3: dodecane, 4: tr idecane, 5: tetradecane, 6: pentadecane, 7: hexadecane, 8: heptadecane, 
9: octadecane, 10: nonadecane, 11: eicosane. 
To see if this method is also suitable for E. coli produced alkanes in TB-medium the 
positive control E. coli BL21 (DE3) with coproduced acyl-ACP reductase and 
aldehyde decarbonylase were measured after 4 h protein production at 37°C. The 
results in Figure 4-36 show the production of five different alkanes: undecane 
(C11H24), dodecane (C12H26), tridecane (C13H28), pentadecane (C15H32), heptadecane 
(C17H36) and one alkene: heptadecene (C17H34). 
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Figure 4-36: SPME-GC-MS measurement of positive control E. coli BL21 (DE3) with 
coproduced acyl-ACP reductase and aldehyde decarbonylase with a sampling time of 30 
min at 37°C. A: TIC, B: EIC m/z 57, C: EIC m/z 71. 1: undecane, 2: dodecane, 3: tr idecane, 
4: pentadecane, 5: heptadecene, 6: heptadecane.  
The alkanes show well detectable peaks with good separation in the TIC, which 
suggests that this method is the right one to analyze the fusion enzyme constructs, 
where we expect lower amounts of alkanes and side products. 
Next to the produced alkanes the production of their precursor, even long-chain 
aldehydes, produced by acyl-ACP reductase can be shown as seen in Figure 4-37. 
The produced aldehydes are tetradecanal, hexadecanal and octadecanal, which 
corresponds to the produced alkanes by the positive control. 
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Figure 4-37: SPME-GC-MS aldehyde detection. SPME-GC-MS measurement of E. coli BL21 
(DE3) with A: produced acyl-ACP reductase (EIC m/z 82), B: aldehyde decarbonylase and 
acyl-ACP reductase (EIC m/z 82) and C: alkane standard C8-C20 (TIC) with a sampling time 
of 30 min at 37°C. 1: tetradecanal, 2: hexadecanal, 3: octadecanal. 
The used EIC m/z 82 was selected to differentiate between alkanes and aldehydes. 
 
4.9.4 Protein Production for Alkane Production using SPME-GC-MS 
Measurements 
The coproduction of acyl-ACP reductase and the fusion proteins CYP4G1-BMR or 
CYP4G2-BMR was performed in E. coli BL21 (DE3), as shown in Figure 4-38. 
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Figure 4-38: Schematic representation of the coexpression for alkane production in E. coli. 
Coproduction of the acyl-ACP reductase on a pCDFDuet-1 plasmid and the CYP4G-BMR 
fusion construct on a pASK-IBA33plus plasmid. 
The best conditions for the coproduction for SPME-GC-MS detection of alkanes had 
to be determined since the conditions for the positive control reaction used in the 
initial tests (coexpression acyl-ACP reductase and aldehyde decarbonylase) are not 
the same. Table 4-5 shows the different tested variables. 
 
Table 4-5: Overview of changed parameters for evaluation of protein production for SPME-
GC-MS measurement of alkanes. 
Variable 1 2 3 4 final 
flask 20 ml GC vial 20 ml GC vial / 100 ml flask 20 ml GC vial 
volume 5 ml 5 ml / 50 ml 5 ml 
temperature for 
protein production 37°C 28°C 28°C and 30 min 37°C 37°C 37°C 
speed during 
protein production 250 rpm 180 rpm 250 rpm 
sample procedure direct first frozen direct 
 
The best conditions were protein production directly in GC vial with 5 ml medium 
volume at 37°C with 250 rpm. The most important parameters were the temperature 
and the direct sample procedure, this lead to the best results for all tested samples, 
as seen in Figure 4-39. The controls: single expression of aldehyde decarbonylase 
or acyl-ACP reductase show the expected sizes at 28 kDa and 38 kDa, respectively. 
The coexpression of acyl-ACP reductase (38 kDa) and aldehyde decarbonylase 
(28 kDa) or CYP4G1-BMR (130 kDa) or CYP4G2-BMR (133 kDa) is showing bands 
at the expected size.  
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Figure 4-39: Western blot analysis of coproduced enzymes. Western blot analysis of E. coli  
BL21 (DE3) with aldehyde decarbonylase (1), acyl-ACP reductase (2), aldehyde 
decarbonylase & acyl-ACP reductase (3), acyl-ACP reductase & CYP4G1-BMR (4) and acyl-
ACP reductase & CYP4G2-BMR (5). t0= time of induction with anhydrotetracycline and/or 
IPTG, 4h = 4 h after induction. In all cases the expected protein size could be detected after 
4 h expression. 
 
4.9.5 SPME-GC-MS Measurements of CYP4G-BMR Constructs 
The results of SPME-GC-MS measurements of CYP4G1-BMR (not shown) and 
CYP4G2-BMR coexpressed with acyl-ACP reductase (Figure 4-40 B) do not show 
new alkanes produced compared to the negative control aldehyde decarbonylase 
(Figure 4-40 A). Whereas for positive control, coexpressed aldehyde decarbonylase 
and acyl-ACP reductase, produced alkanes (Figure 4-40 C, 1-4) are detectable. 
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Figure 4-40: EIC (m/z 71) of SPME-GC-MS measurement of E. coli BL21 (DE3) with 
A: aldehyde decarbonylase B: coexpressed CYP4G2-BMR and acyl-ACP reductase 
C: coexpressed aldehyde decarbonylase and acyl-ACP reductase and D: alkane standard 
C8-C20 with a sampling time of 30 min at 37°C. 1: tridecane, 2: pentadecane, 3: 
heptadecene, 4: heptadecane. 
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4.9.6 Discussion of GC-MS Measurements of Alkane producing 
Constructs 
This chapter showed the construction of a coexpression whole-cell E. coli system 
producing alkanes and the establishment of a GC-MS method able to detect the 
produced alkanes and aldehydes. Schirmer and coworkers showed that alkane 
production using acyl-ACP reductase and aldehyde decarbonylase from 
cyanobacteria is possible in E. coli [80]. The enzymes selected for this study, acyl-
ACP reductase and aldehyde decarbonylase, both from Nostoc punctiforme, were 
never coexpressed before in E. coli and served as positive control. Many researchers 
focused on the optimization of biofuel production by metabolic engineering [81-82]. 
Another way to achieve different products could be the use of insect P450s instead 
of the aldehyde decarbonylase. Therefore, the alkane producing system was 
adjusted to the coexpression with the new insect P450 fusion constructs CYP4G1-
BMR and CYP4G2-BMR instead of the N. punctiforme aldehyde decarbonylase. 
The GC-MS method for alkane detection was evaluated using the alkane standard 
C8-C20 and the alkane positive control acyl-ACP reductase coproduced with 
aldehyde decarbonylase from Nostoc punctiforme in E. coli. The first measurements 
were performed on a GC-MS CT1128 (Constellation Technology Corporation) and 
more detailed analysis were performed on a GC-MS 5973 (Agilent Technologies). 
Using those two instruments the variables influencing the outcome, like expression 
conditions, sample preparation and GC-MS method were determined. This lead to 
the final settings shown in Table 4-3 and Table 4-4. The GC method was only 
adjusted slightly according to the used instrument. Due to the necessity of the alkane 
extraction from the samples for these GC-MS measurements a loss of product is 
inevitable. To avoid an extraction step a new GC-MS method was established for this 
application, SPME-GC-MS. This method avoids all steps of conventional liquid-liquid 
extraction, like extraction and concentration [83]. The sample was directly extracted 
to the SPME fiber coating, in this case polydimethylsiloxane. Another advantage of 
this method was that the expression can be performed in TB medium which increased 
the protein yield and by this the potential alkane production. For this method the best 
protein production conditions with subsequent analysis were examined (Table 4-5) 
and expression in TB, in GC vials for 4 h with direct analysis afterwards showed the 
best results. This method enabled the detection of the aldehydes produced by acyl-
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ACP reductase and the detection of the alkanes produced by the positive control 
(Figure 4-36 and Figure 4-37). The acyl-ACP reductase produced even numbered 
aldehydes (tetradecanal, hexadecanal and octadecanal) which were converted into 
uneven numbered alkanes (tridecane, pentadecane and heptadecane) by aldehyde 
decarbonylase. Furthermore, the alkanes, undecane and dodecane plus the alkene, 
heptadecene, were produced. The alkanes, undecane and dodecane, for which the 
corresponding aldehydes were not detected are only present in very low 
concentrations. Alkanes are better detectable than their corresponding aldehydes, 
this could be why only the alkanes were detected. 
In this study it was shown for the first time that aldehyde decarbonylase and acyl-
ACP reductase from Nostoc punctiforme produce the alkanes, undecane, dodecane, 
tridecane and pentadecane, when coexpressed on pASK-IBA33plus and pCDFDuet-
1 in E. coli. The study performed by Schirmer et al. observed only heptadecane 
production for the cyanobacterium N. punctiforme [80]. The detection of more alkanes 
could be due to the fatty acids produced by E. coli (until the length of C17 [84]), which 
serve as available substrate for the acyl-ACP reductase. 
The same setup was used for the coexpression of acyl-ACP reductase with the fusion 
constructs CYP4G1-BMR and CYP4G2-BMR. The coexpression showed promising 
protein expression with stable produced protein in the expected size (Figure 4-39). 
For both constructs no alkane production could be detected. Since the purification is 
ruled out by these experiments as a possible reason for the missing enzyme activity 
the construction of the fusion could be the reason. The linker length is known to 
strongly influence the enzyme activity, since it regulates the localization of the BMR 
towards the heme domain and by this it regulates the electron flow [46,  85]. Another 
part of the construction which has a big influence on the activity is the BMR domain 
itself. The domain might not be able to interact with the insect P450 as expected 
although mechanism similarities were shown in from former studies [25]. These two 
important factors were analyzed in the following chapter. 
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4.10 Construction of Optimized Fusion Enzymes 
To investigate the reasons for the missing alkane production new approaches were 
developed. A new CYP4G from Forficula auricularia was used for fusion enzyme 
construction. Furthermore new fusion enzymes with either a shorter linker or no 
linker were designed and constructed to eliminate the linker length as a reason for 
the inactive fusion constructs. 
 
4.10.1 Construction of a Fusion Enzyme based on CYP4G from Forficula 
auricularia 
Previously it was shown that the European earwig Forficula auricularia larvae 
produce alkanes (n-tridecane and n-pentadecane) as defense measures [86]. The 
genome of F. auricularia was available [51] and screened (by R. Lehmann) for CYP4G 
coding sequences, which have been suggested to be involved in the alkane synthesis 
[29]. The following sequence (CYP4GF) (Figure 4-41) was found and based on this 
primers were designed (Table A.2.4-3), which flanked the CYP4GF sequence. 
 
CYP4G1    1 -----MAVEVVQETLQQAASSSSTTVLGFSPMLTTLVGTLVAMALYEYWRRNSREYRMVANIPSPPELPILGQAHVAAGL 
CYP4GF    1 MSFADALEMVATTPEINPEVGATETVSASSSIFWYLLVPAISLYIFYYWFSRRRLNEMASKIPGLDGFPVLGVAHRFFGK 
 
CYP4G1   76 SNAEILAVGLGYLNKYG-ETMKAWLGNVLLVFLTNPSDIELILSGHQHLTKAEEYRYFKPWFGDGLLISNGHHWRHHRKM 
CYP4GF   81 THDEIFTELMEYIQESGDKAGKLWLGPRLHVYLLDPRDIEIILGSSVHLDKSPEYRFFEPWLGDGLLITSGNKWRRHRKI 
 
CYP4G1  155 IAPTFHQSILKSFVPTFVDHSKAVVARMGLEAGKSFDVHDYMSQTTVDILLSTAMGVKKLPEGNKSFEYAQAVVDMCDII 
CYP4GF  161 IAPTFHLNVLKSFVELFNKNTHDVIERMKKQHGKTFDAHDFMSECTVEILMETAMGVDKKGHKN-GFEYAMAVMKMSNIL 
 
CYP4G1  235 HKRQVKLLYRLDSIYKFTKLREKGDRMMNIILGMTSKVVKDRKENFQEESRAIVEEISTPVASTPASKKEGLRDDLDDID 
CYP4GF  240 HTRHINPFLRLNWVFNLTKTSKEQVKLLETIHGVTNKIIENKKKAFDSGQKRYITSSSTKEEDSALSANKGLKDDLDAHD 
 
CYP4G1  315 ENDVGAKRRLALLDAMVEMAKNPDIEWNEKDIMDEVNTIMFEGHDTTSAGSSFALCMMGIHKDIQAKVFAEQKAIFGDNM 
CYP4GF  320 D-DIGQKKRLAFLDYLLESRDN-GNNFTEDEIREEVNTIMFEGHDTTAAGSSFFLSVMGVHPEIQDKIYEELDAIFGD-S 
 
CYP4G1  395 LRDCTFADTMEMKYLERVILETLRLYPPVPLIARRLDYDLKLASGP-YTVPKGTTVIVLQYCVHRRPDIYPNPTKFDPDN 
CYP4GF  397 DRDCTFQDTLEMKYLERCLLESLRMYPPVPLIAREIKKDVRLASNTNIVLPAFSTIIIGTYALHRDKDIFPNPDVFDPDN 
 
CYP4G1  474 FLPERMANRHYYSFIPFSAGPRSCVGRKYAMLKLKVLLSTIVRNYIVHSTDTEADFKLQADIILKLENGFNVSLEKRQYA 
CYP4GF  477 FLPEKQANRHYYSYIPFSAGPRSCVGRKFAMLKLKILLSTILRKFRIEADTEEKDFKLQADLILKRADGFPIRLVPRNRG 
 
CYP4G1  554 TVAGG 
CYP4GF  557 KAIA- 
 
Figure 4-41: Sequence Alignment of CYP4G1 and CYP4G from F. auricularia (CYP4GF). 
Black and gray shading represent amino acid identity and similarity, respectively.  
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mRNA from ten earwig larvae (collected by T. Gasch), approximately 200 mg, was 
isolated and cDNA was synthesized from it. Figure 4-42 shows the procedure of the 
CYP4GForficula-BMR construction starting with ten earwigs. The cDNA was used as 
template for PCR with primers (Table A.2.4-3) for CYP4G amplification. The resulted 
PCR fragment was cloned into pCR-Blunt II TOPO for multiplication. The plasmid, 
pCR_CYP4GForficula, was amplified in E. coli TOP10 cells and isolated. 
pCR_CYP4GForficula was used as template for PCR using primers (Table A.2.4-1) 
to extend the gene by His6-tag and BsaI cloning sites. After double digestion of the 
PCR fragment and pASK-IBA33plus with BsaI the fragment and the backbone were 
ligated and yielded the construct pASK-IBA33_CYP4GForficula. E. coli TOP10 cells 
were transformed with this plasmid. After verification of the sequence (primers listed 
in Table A.2.4-2) pASK-IBA33_CYP4GForficula was used as template for PCR with 
the primers (Table A.2.4-1) to amplify the CYP4G Forficula gene without His6-tag 
and extended by XbaI (5’-site) and SalI (3’-site) sites. After double digestion of the 
PCR fragment and pASK-IBA33_BM3 with XbaI and SalI the PCR fragment and 
backbone were ligated and E. coli TOP10 cells were transformed with the new 
construct pASK-IBA33_CYP4GForficula-BMR. After verification of the sequence 
(primers listed in Table A.2.4-2), E. coli BL21 cells (expression strain) were 
transformed with the plasmid.  
Results and Discussion 
 
 
89 
 
 
Figure 4-42: Schematic representation of CYP4G Forficula-BMR fusion enzyme construction 
based on isolated mRNA from ten earwig larvae. 
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4.10.2 CYP4G-BMR Fusion Enzyme with Shortened Linker 
The construction of the CYP-BMR short linker construct used the former used 
CYP4G-BMR fusion construct as template. Literature shows that the linker length of 
P450 fusion constructs has an enormous impact on the constructs activity and 
stability [62]. Figure 4-43 shows the comparison of the former used linker and the new 
shorter linker. 
Linker:   SKKIPLGGIPSPTEQSAKKVRKKAENAHN 
short Linker:            SPTEQSAKKVRKKAENAHN 
 
Figure 4-43: Sequence Alignment of the former used linker and the new shortened linker. 
To reduce the former linker to this shortened sequences new reverse primers with a 
SalI restriction enzyme site were designed (Table A.2.4-1). As forward primer the 
same primer as before with an XbaI site can be used. These primer pairs were used 
to create a CYP4G with an N-terminal XbaI site and a shortened linker region with a 
SalI site. The construction was performed as described in 3.14 and shown in Figure 
4-44. This yielded the two constructs pASK-IBA33-CYP4G1-BMRshortLinker and 
pASK-IBA33-CYP4G2-BMRshortLinker.  
 
Figure 4-44: Schematic representation of insect P450-BMR fusion construction with 
shortened linker. 
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4.10.3 Construction of a Plasmid with Non-Fusion CYP4G and hCPR 
To exclude the interaction of the BMR domain and the insect P450 domain as a 
reason for the missing activity a non-fusion construct on plasmid with an insect P450 
and hCPR as reductase designed and constructed. Figure 4-45 shows a sequence 
alignment of the BMR domain and hCPR showing conserved motives. Otherwise the 
sequence homology is not that high. 
 
BMR     1 -------------------------------------------------------------------------------M 
hCPR    1 MINMGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTG 
 
BMR     2 TPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLD-------SHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLD 
hCPR   81 RNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQ 
 
BMR    75 QASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDI 
hCPR  161 ETDVDLSG-VKFAVFGLGNKTYEHFNAMG-KYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEA 
 
BMR   155 ENSED--NKSTLSLQFVDSAADMPLAKMHGAFSTN--------------VVASKELQQPGSARSTRHLEIELP-KEASYQ 
hCPR  239 TGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYE 
 
BMR   218 EGDHLGVIPRNYEGIVNRVTARFG--LDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVC 
hCPR  319 SGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASE 
 
BMR   296 PP-----HKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITVSV 
hCPR  399 PSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVV 
 
BMR   371 VSGEAWSGYGEYKGIASNYLAELQ----EGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQG 
hCPR  479 VEYETKAGR-INKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQG 
 
BMR   447 QSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQ 
hCPR  558 KEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARN 
 
BMR   527 MAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAG 
hCPR  638 MARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS- 
 
Figure 4-45: Sequence alignment of BMR and hCPR. Black and gray shading represent 
amino acid identity and similarity, respectively.  
 
The construction was performed as described in 3.16 and shown in Figure 4-46. This 
yielded the constructs pET-Duet-1_CYP4G1_hCPR, pET-Duet-1_CYP4G2_hCPR 
and pET-Duet-1_CYP4GF_hCPR. 
Results and Discussion 
 
 
92 
 
 
Figure 4-46: Schematic representation of the construction of plasmid with non-fusion P450 
and hCPR. 
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4.10.4 Coexpression of New Fusion Enzyme Constructs with Acyl-ACP 
Reductase in E. coli 
The coexpression of the new constructs with acyl-ACP reductase was performed as 
described in 3.20 and 4.9.4. 
 
Figure 4-47: Western blot analysis of co-expressed constructs with acyl-ACP reductase in 
E. coli BL21 (DE3). 1: CYP4G1-BMR_shortLinker & acyl-ACP reductase, 2: CYP4G2-
BMR_shortLinker & acyl-ACP reductase, 3: CYP4GForficula-BMR_shortLinker & acyl-ACP 
reductase. 
The Western blot analysis in Figure 4-47 shows that the coexpression of CYP4G1-
BMR_shortLinker & acyl-ACP reductase and CYP4GForficula-BMR_shortLinker & 
acyl-ACP reductase worked. They show the expected protein sizes for the 
insectCYP-BMR_shortLinker constructs at 130 kDa and the acyl-ACP reductase at 
38 kDa. The coexpression of CYP4G2-BMR_shortLinker and acyl-ACP reductase did 
not show the expected bands in this particular expression. The constructs without 
linker were not tested. 
 
4.10.5 SPME Measurements of Optimized Coproduced Constructs 
The SPME measurements of the optimized coproduced constructs were performed 
as described in section 3.30.4 and do not show any alkane products. The results 
look similar to the coexpression of CYP4G2-BMR and acyl-ACP reductase shown in 
Figure 4-40. 
 
4.10.6 SPME Measurements with added Aldehyde (no Coexpression) 
To verify if the acyl-ACP reductase produced long-chain aldehydes are not usable 
by the CYP4G-BMR constructs, the known CYP4G substrate octadecanal and C8-
C20 aldehyde standard were use as substrates. This replaced the necessary 
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coexpression system used before. Tested were single expressed fusion enzyme 
constructs. The constructs and results are shown in Table 4-6. 
 
Table 4-6: SPME-GC-MS measured constructs with added aldehydes. 
Construct Added Substrate Product 
CYP4G1-BMR 
octadecanal 
heptadecane 
(contamination) 
C8-C20 aldehydes 
CYP4G2-BMR 
octadecanal 
C8-C20 aldehydes 
CYP4GForficula-BMR 
octadecanal 
C8-C20 aldehydes 
CYP4G1-BMRshortLinker 
octadecanal 
C8-C20 aldehydes 
CYP4G2-BMRshortLinker 
octadecanal 
C8-C20 aldehydes 
CYP4GForficula-BMRshortLinker 
octadecanal 
C8-C20 aldehydes 
CYP4GForficula + hCPR 
octadecanal 
C8-C20 aldehydes 
 
Heptadecane was detected in all measured samples. It is not a CYP4G-BMR product, 
since it was shown that it is a contamination of the substrates. Heptadecane was 
present in all controls (medium and acyl-ACP reductase produced in E. coli) at the 
same octadecanal : heptadecane ratio of 1 : 2.5. 
 
4.10.7 Discussion of SPME Measurements of Optimized Fusion 
Constructs 
This chapter showed the construction of the F. auricularia CYP4G-BMR fusion 
enzyme and the shortening of the fusion enzyme linker as well as the construction 
of non-fusion CYP4G hCPR constructs. The original linker length of the insect P450-
BMR fusion enzymes was selected longer as the standard BM3 linker in order to 
achieve high flexibility, which is promoted by the high occurrence of the amino acids 
glycine, threonine and serine [61,  87]. This should enable the best possible orientation 
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of the BMR domain towards the exchanged heme domain. A disadvantage of the 
longer linker was the higher amount of potential protease cleavage sites. The results 
of the protein purification at room temperature (4.4.2.2) showed that the fusion 
protein cleaves at the linker domain. To increase the construct stability and possibly 
the domain interaction the linker length was reduced by ten amino acids. 
F. auricularia larvae were shown to produce alkanes as chemical defense [86] and 
thus this organism was a good source for the identification of new CYP4G genes. 
For the investigation of a novel insect CYP4G from F. auricularia the CYP4G was 
amplified from mRNA. Based on CYP4GForficula, CYP4GF-BMR as well as CYP4GF-
BMR_shortLinker were constructed. The CYP4GF could be involved in n-tridecane 
and n-pentadecane production. Furthermore, coexpression plasmids of insect 
CYP4G and hCPR were constructed to examine if the CYP4G BMR interaction is not 
as effective as expected. hCPR was selected since it was shown before that it is 
able to deliver the necessary electrons to insect P450s [88]. The two genes were 
cloned on a pETDuet-1 vector, which offers two multiple cloning sites and two t7 
promoters. In addition it is compatible with the pCDFDuet-1 vector used for acyl-ACP 
reductase (Novagen user protocol TB340). The constructs were tested on their ability 
to produce alkanes from aldehydes which were earlier produced by acyl-ACP 
reductase. The coproduced constructs were investigated by SPME-GC-MS as shown 
before (4.9.3). For none of the measured constructs alkane production could be 
detected. For the investigation of the missing aldehyde catalyzation the constructs 
were expressed alone in E. coli, without the presence of acyl-ACP reductase, and 
aldehydes were added to the culture. The results of the SPME-GC-MS measurements 
with added aldehydes show no activity for any of the tested CYP4G constructs. This 
suggests that either the aldehydes did not reach the catalytic center of the enzymes, 
which could be explained by the same result for each measured construct and control 
groups. Moreover, the constructs could be expressed inactive due to wrong folding, 
since the expression was performed at 37°C, which was shown before to have an 
impact on the constructs solubility (4.4.2.3). Additionally, they could have not 
implemented the heme in the catalytic center and thus were not able to catalyze the 
substrate decarbonylation. It was shown for the CYP6A1-BMR that heme loss can 
occur (4.6.3). A study that could explain the missing activity for all tested fusion 
enzymes showed that fusing a reductase to a P450 may produce a catalyst with 
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altered properties when compared to the non-fused equivalent [79]. However this 
cannot be the case for the non-fused CYP4G hCPR constructs.  
The concept of insect P450 fusion enzyme should be the foundation for future work. 
Activity optimization should focus on one construct. For this the linker length should 
be altered in various length and the enzyme activity of those constructs should be 
determined by SPME-GC-MS. 
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5 Conclusions and Outlook 
To unlock the enormous potential of insect P450 for technical applications, chemical 
synthesis and for their molecular and biochemical characterization they have to be 
made available in sufficient quality and quantity. This study applies one strategy that 
enables the characterization of insect P450 by using the “Molecular Lego” approach 
for the construction and soluble expression of insect P450-BMR fusion enzymes in 
E. coli. Four different construct variations were created and tested: insect P450-BMR 
with and without BM3 N-terminus, insect P450-BMR with shortened linker and 
coexpression of insect P450 with human CPR. Soluble expression and purification 
without detergents was shown for the CYP6 constructs with and without BM3 N-
terminus. GC- and LC-MS methods were established for their activity determination. 
The lack of detectable activity let us to speculate that with current knowledge a 
whole-cell approach might be beneficial for the P450 activity. Thus, a whole-cell 
coexpression system for alkane production was established. The coexpression 
system consisted of a CYP4G construct (without BM3 N-terminus, or with shortened 
linker or with human CPR) and the blue algae acyl-ACP reductase. For the aldehyde 
and alkane detection a SPME-GC-MS method was established. The positive control 
coexpression system of blue algae acyl-ACP reductase and aldehyde decarbonylase 
showed for the first time alkane production in E. coli with this particular protein 
combination.  
This study showed that the whole cell approach is a good foundation for further 
approaches. The expression of the constructed insect P450-BMR fusion constructs 
in another expression system, like insect cells or yeast, which were shown to be of 
great advantage for insect enzyme production could lead to active fusion constructs. 
Further studies on the linker region and the interaction of the insect P450 and BMR 
domain would add valuable information to our current understanding of insect P450s. 
Possible target sites for optimization of the linker region are the linker length and 
composition. They could be explored in a site-directed or random manner to identify 
potential improvement of activity, for example enhanced flexibility. Furthermore, the 
identification and elimination of potential protease cleavage sites in the linker could 
enhance the construct stability. Moreover, the interaction of the insect P450 and 
BMR resulting in their electron transfer rate and coupling efficiencies is a possible 
subject for optimization. The RhF reductase has been proven to be a versatile 
reductase partner and can be used as surrogate reductase for P450s without a known 
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natural redox partner [89]. Until now, no X-ray crystal structure for insect P450s is 
available, which could be useful for the determination of possible interaction sites 
with P450 reductases [60].  
All results obtained in this study build a solid foundation for future work on insect 
P450s. The construction of fusion enzymes and the possible optimization procedures 
mentioned above represent a promising strategy for the utilization of insect P450s. 
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Index of abbreviations 
°C Degree Celsius 
A Absorbance 
Abs Absorbance 
ACP Acyl carrier protein 
BCA Bicinchoninic acid 
BM3 CYP1A102 from Bacillus megaterium 
BMR BM3 reductase 
bp Base pair 
cDNA Complementary deoxyribonucleic acid 
CYP Cytochrome P450 monooxygenase 
D. melanogaster Drosophila melanogaster 
ddH2O Double-distilled water 
DEAE Diethylaminoethanol 
DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EIC Extracted ion chromatogram 
F. auricularia Forficula auricularia 
FAD Flavin adenine dinucleotide 
FMN Flavin mononucleotide 
fwd Forward 
g Relative centrifugal force 
h Hour 
hCPR Human P450 reductase 
His6-tag Hexa histidine tag 
IMAC Immobilized Metal Affinity Chromatography 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IS Internal standard 
LB Luria-Bertani broth 
LIC Ligation-independent cloning 
M Mol/l 
M. domestica Musca domestica 
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M9 M9 minimal medium 
min Minute 
mRNA Messenger ribonucleic acid 
N. punctiforme Nostoc punctiforme 
NADP+ Nicotinamide adenine dinucleotide phosphate 
NADPH Dihydronicotinamide-adenine dinucleotide phosphate 
NTA Nitrilotriacetic acid 
ORF Open reading frame 
p.a. Analytical grade 
P450 Cytochrome P450 monooxygenase 
PCNA Proliferating cell nuclear agent 
PCR Polymerase chain reaction 
pNCA p-nitrophenoxycarboxylic 
PVDF Polyvinylidene difluoride 
rev Reverse 
RNA Ribonucleic acid 
RT Room temperature 
TAE Buffer containing tris base, acetic acid and EDTA 
TB Terrific broth medium 
TBS Tris buffered saline 
TBS/T Tris buffered saline with Tween 20 
TIC Total ion chromatogram 
Tris Tris(hydroxymethyl)aminomethane 
TSS Transformation and storage solution 
 
Moreover, the usual three-letter or one-letter codes for amino acids were used as 
well as standard SI units. 
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A Appendix 
A.1 Pretests: hCPR and BM3 production, purification and activity 
measurements 
A.1.1 Production and purification of human reductase 
We produced hCPR in TB with 1 mM riboflavin, which is necessary for the build-up 
of FAD and FMN. The standard conditions of 4.5 h at 37°C for the protein production 
and purification with CHAPS and β-mercaptoethanol as detergents over a Talon 
column gave low amounts of very unpure protein. This is why different conditions to 
increase both amount and purity were tested. Table 4-2 summarizes tested conditions 
used for production and purification of hCPR. 
 
Table A.1.1-1: Overview Expression and Purification Conditions of hCPR expressed in 
E. coli BL21. 
Expres
-sion 
Cell Lysis 
Centrifu
-gation 
Detergents Column Buffer 
4.5 h 
37°C 
microfluidizer 1x 
0.1% CHAPS, 1 mM 
β-mercaptoethanol Talon Tris 
4.5 h 
37°C 
microfluidizer + 
ultrasonic 
1x 
0.2% Triton X-100, 
0.2% Na-cholate 
Ni-NTA 
Na-phosphate 
+ 20% glycerol 
4 h 
42°C 
microfluidizer + 
ultrasonic 
2x 
0.5% Triton X-100, 
0.5% Na-cholate 
Ni-NTA 
Na-phosphate 
+ 20% glycerol 
48 h 
42°C 
microfluidizer + 
ultrasonic 
2x 
0.5% Triton X-100, 
0.5% Na-cholate 
Ni-NTA 
Na-phosphate 
+ 20% glycerol 
4 h 
28°C 
microfluidizer + 
ultrasonic 
2x 
0.5% Triton X-100, 
0.5% Na-cholate 
Ni-NTA 
Na-phosphate 
+ 20% glycerol 
48 h 
28°C 
microfluidizer + 
ultrasonic 
2x 
0.5% Triton X-100, 
0.5% Na-cholate 
Ni-NTA 
Na-phosphate 
+ 20% glycerol 
 
From our tests we identified the best condition for recombinant production and 
purification of hCPR as: protein production for 4 h at 28°C, resuspension of the 
pellets in lysis buffer try 2 (Table A2-10) with 0.5% Triton X-100, a nonionic 
detergent, and 0.5% Na-cholate, an anionic detergent, which are both widely used 
for solubilization of membrane proteins. Next cells were lysed twice using 
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microfluidizer followed by 1 h centrifugation at 75600 g to harvest the cell debris. 
Cell debris was resuspended in the same lysis buffer and sonicated for 10 min with 
30% energy followed by final centrifugation for 30 min at 75600 g. Collected 
supernatant was loaded on a Ni-NTA column using IMAC buffer A try 2-6 (Table 
A2-10) supplemented with Triton X-100 and Na-cholate. 
 
 
Figure A.1.1-1: SDS-PAGE of human reductase purification samples. Comparison of first 
purification with Talon as column raisin (Figure 4-8 A) and optimized expression and 
purification with Ni-NTA as column raisin (Figure 4-8 B). A: Fractions E1-E4: hCPR produced 
under standard conditions and purified via Talon column. B: Fractions E5-E11: hCPR 
produced at 28°C for 4 h, buffers supplemented with Triton X-100 and sodium cholate and 
purified via Ni-NTA column. 
To avoid interference of Triton X-100 and Na-cholate on enzyme activity the buffer 
exchange was performed via ion exchange chromatography. hCPR has a pI of 5.77 
which makes it suitable for an anion exchange. It was performed using Source Q15 
(polymeric, strong anion exchanger) column. The pooled IMAC fractions (7 ml) were 
diluted with anion exchange buffer A1 (Table A2-10) to a final volume of 70 ml to 
reduce the salt concentration and enable binding. The loaded samples were washed 
with anion exchange buffer A2 (Table A2-10) and then eluted with 500 mM NaCl. The 
final protein amount was determined by comparison to a BSA standard curve on a 
SDS-PAGE gel (Figure 4-9 A). We achieved a final concentration of ca. 2 mg/ml 
hCPR. The yellow color caused by FAD and FMN in the reductase is clearly visible 
in the highest concentrated elution fraction E15 (Figure A.1.1-2 B). 
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Figure A.1.1-2: hCPR samples after anion exchange purification. A: SDS-PAGE gel of anion 
exchanged purified hCPR fractions E12-E19. B: Corresponding samples of fractions E14-
E17. The yellow color caused by FAD and FMN is clearly visible in fraction E15. 
 
A.1.2 Production and purification of BM3 
The expression of BM3 was performed in TB medium with 1 mM δ-aminolevulinic 
acid, 1 mM thiamine and 1 mM riboflavin. The δ-aminolevulinic acid and thiamine are 
important for the build-up of the heme ring in the P450 domain and riboflavin for FAD 
and FMN in the reductase domain. The 4.5 h long expression at 37°C and 180 rpm 
was induced at an OD600 of 1. Cells were harvested by centrifugation at 17000 g for 
10 min at 10°C. 
Pelleted cells were resuspended in IMAC buffer A (Table A2-11) and lysed twice 
using microfluidizer prior purification. Cell debris was removed by centrifugation at 
75000 g for 30 min at 10°C and resulting supernatant was loaded on a Ni-NTA 
column. Recombinant BM3 was eluted by IMAC buffer B (Table A2-11) containing 
200 mM imidazole, Figure A.1.2-1. 
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Figure A.1.2-1: IMAC purification of recombinant produced BM3. A: Elution profile of IMAC 
purification of BM3 using Ni-NTA column and imidazole as eluent. B: SDS-PAGE of IMAC 
purified BM3 fractions E5-E11 and BSA as comparison for protein amount determination. 
C: Corresponding BM3 elution fraction E5-E11. The red color is caused by the incorporated 
heme group. 
BM3 has a pI of 5.37 which makes it suitable for an anion exchange. The anion 
exchange was performed using DEAE-Sepharose (weak anion exchanger) to remove 
imidazole which was shown to inhibit P450 reactions [90]. To enable binding on the 
column the salt content of the eluted fraction was reduced by adding 10 volumes of 
anion exchange buffer A (Table A2-11) to the samples. 
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Figure A.1.2-2: Ion exchange purification of recombinant produced BM3. A: Elution profile 
of anion exchange purification of BM3 over DEAE-Sepharose column eluted with sodium 
chloride. B: SDS-PAGE of anion exchange purified BM3 fractions E32-E39 with BSA as 
comparison for protein amount determination. 
BM3 was eluted with an increasing gradient from 0 to 500 mM sodium chloride (Figure 
A.1.2-2 A). The SDS-PAGE gel (Figure A.1.2-2 B) shows unimpaired BM3 at the 
expected size of 130 kDa in lower concentrations than the IMAC purified fractions 
(Figure 4-10 B). 
A.1.3 Photometric enzyme activity measurements of purified hCPR 
The photometric analysis of the hCPR activity is based on the measurement at 550 
nm of the absorbance change of the surrogate substrate cytochrome c from its 
oxidized (ferrocytochrome c) to its reduced form (ferricytochrome c), Figure A.1.3-1.  
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Figure A.1.3-1: Electron flow from NADPH to cytochrome c and the color change from orange 
(cytochrome c (ox)) to pink (cytochrome c (red)). 
 
The kinetic measurements of recombinant hCPR were performed at 550 nm for 3 min. 
The results (Figure A.1.3-2) show that the highest enzymatic activity of purified hCPR 
can be achieved when the purification was performed with CHAPS. 
 
Figure A.1.3-2: Kinetic measurements of purified hCPR with cytochrome c at 550 nm for 
3 min.  
A.1.4 Photometric enzyme activity measurements of purified BM3 
The enzyme activity of BM3 can be tested directly by the photometric pNCA-assay, 
which detects the turnover of the P450 surrogate substrate pNCA (Figure A.1.4-1), 
or indirectly by the photometric measurements of the NADPH conversion by the BMR 
domain. 
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Figure A.1.4-1: Kinetic measurements of purified BM3 (45 µg/ml) with pNCA as surrogate 
substrate at 410 nm for 3 min. 
 
Figure A.1.4-2: Kinetic measurements of purified BM3 (45 µg/ml) with SDS as substrate at 
340 nm for 3 min. 
 
  
Appendix 
 
 
118 
 
A.2 Materials 
A.2.1 Chemicals 
Table A.2.1-1: Chemicals used in this study. 
Substance Supplier Catalog number 
(±)-Citronellal ≥ 95% Sigma-Aldrich 27470-100ML-F 
(±)-Gossypol from cotton seeds Sigma-Aldrich G8761 
1-Nonadecene TCI SO349 
1-Nonene Fluka 74323 
2-Mercaptoethanol Bio-Rad 161-0710 
2-Propanol, 70% Roth CN09.4 
2-Propanol, Rotisolv Roth 73431 
4,4'-DDD Sigma-Aldrich 35486 
4,4'-DDE Sigma-Aldrich 35487 
4,4'-DDT Sigma-Aldrich 31041 
4-Methyl-5-thiazolethanol Sigma-Aldrich W320404-SAMPLE-K 
5-Aminolevulinic acid hydrochloride Roth 8451.2 
5-Aminolevulinic acid hydrochloride Sigma-Aldrich A3785 
7-Ethoxycoumarin Sigma-Aldrich E1379 
Acetic acid ethyl ester GC Ultra Grade Roth KK42.1 
Acetone, 99.5% Roth 5025.5 
Acetonitrile ROTISOLV® HPLC Gradient 
Grade Roth 8825.2 
Agar-Agar, bacteriological Roth 2266.2 
Aldrin Sigma-Aldrich 36666 
Alkane standard solution C8-C20, 
analytical standard, contains C8-C20, ~40 
mg/L each, in hexane 
Sigma-Aldrich 4070 
Ampicillin Sodium Salt Roth K029.2 
Anhydrotetracyclin iba  
Carbenicillin disodium salt Roth 6344.2 
CHAPS Roth 1479.4 
Chlordane Sigma-Aldrich 45378 
Chlordene Sigma-Aldrich 31517 
Citral 95% Sigma-Aldrich C83007 
Cyromazine Sigma-Aldrich 45414 
Cytochrome c from equine heart Sigma-Aldrich C2506 
D (+) Glucose anhydrous Roth HN06.3 
Decanal ≥98% (GC), liquid Sigma-Aldrich D7384 
Deltamethrin Sigma-Aldrich 45423 
Dichlormethane Sigma-Aldrich 32222 
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Substance Supplier Catalog number 
Dieldrin Sigma-Aldrich 33491 
Dimethyl sulfoxide for molecular biology Roth A994.2 
Dimethyl sulfoxide Rotidry Roth 5179.1 
Di-Potassium hydrogen phosphate Roth P749.2 
di-Sodium hydrogen phosphate dihydrate Roth 4984.2 
Dodecyl aldehyde 92% Sigma-Aldrich D222003  
Ethanol 99.5% denatured with 1% MEK VWR 85.033.460 
Ethanol, Rotipuran Roth 9065.2 
Ethylenediamine tetraacetic acid Roth CN06.1 
Flavin adenine dinucleotide disodium salt 
hydrate Sigma-Aldrich F6625 
GelGreenTM Nucleic Acid Stain Biotium 41005 
Glycerol Rotipuran Roth 3783.2 
Glycine Pufferan Roth 3908.3 
Hexane Sigma-Aldrich 32293 
Hydrochloric acid 25 % Roth X897.1 
Imidacloprid Sigma-Aldrich 37894 
Imidacloprid-Olefin Dr. Ehrenstorfer  C14283760 
Imidazole Sigma-Aldrich I2399 
IPTG Roth CN08.3 
Iron (III) chloride reagent grade Sigma-Aldrich 157740 
Kanamycin sulphate Roth T832.1 
Laemmli Sample buffer 3x Bio-Rad 161-0737 
LB Broth (Lennox) Roth X964.3 
Magnesium chloride hexahydrate Roth 2189.2 
Magnesium sulfate Sigma-Aldrich M2643 
Methanol Rotisolv Roth 7432.1 
Mucasol Sigma-Aldrich Z637203 
Nonanal 95% Sigma-Aldrich N30803 
Octadecanal TCI O0368 
Oleic acid, Rotichrom GC Roth 5362.1 
Permethrin Fluka 45614 
Polyethylene glycol 6000 Roth 0158.4 
Potassium chloride Roth HN02.1 
Potassium dihydrogen phosphate Roth P018.2 
Riboflavine ≥ 97% Ph.Eur. Roth 9607.1 
Riboflavine 5'monophosphate sodium salt 
hydrate Sigma-Aldrich F2253 
Roti-Blue quick Roth 4829.2 
Rotiphorese® 10x SDS-PAGE Roth 3060 
SDS Pellets ≥ 99% Roth CN303 
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Substance Supplier Catalog number 
SDS, ultra pure Roth 2326.1 
Sodium chloride Roth 9265.2 
Sodium choleate Sigma-Aldrich S9875 
Sodium dihydrogen phosphate dihydrate Roth T879.2 
Sodium hydroxide solution Roth KK71.1 
Sodium sulfate Sigma-Aldrich 239313 
Streptomycin sulfate Roth HP66.1 
Terrific-Broth-Medium Roth X972.3 
Thiacloprid Sigma-Aldrich 37905 
Thiamin hydrochloride Roth T911.2 
Tris Pufferan Roth AE15.3 
Tris-HCl Roth 9090.3 
Triton X-100 Roth 3051.3 
Tween 20 Roth 9127.1 
Umbelliferone Roth 5371.1 
β-Nicotineamide adenine dinucleotide 
phosphate reduced tetra 
(cyclohexylammonium) salt 
Sigma-Aldrich N5130 
 
A.2.2 Consumables 
Table A.2.2-1: Consumables used in this study. 
Material Supplier Catalog number 
10 ml Disposable syringes Injekt®, Luer-
fitting, Braun Roth 0058.1 
20 ml Disposable syringes Injekt®, Luer-
fitting, Braun Roth 0059.1 
4–15% Mini-PROTEAN® TGX™ Gels Bio-Rad 456-1086 
5 ml Disposable syringes Injekt®, Luer-
fitting, Braun Roth 00057.1 
Corning®96 well Plates GBO 655185 
Extra Thick Blot Paper Bio-Rad 1703965 
Handschuhe TouchNTuff® Ansell 92-600 
Parafilm® M Roth H666.1 
Protino Ni-NTA Agarose Macherey-Nagel 745.400.100 
Qsepharose Fast Flow GE Healthcare 17-0510-01 
Roti®-Store cryo vials Roth P730.2 
Rotilabo®-syringe filters, 0.22 µm Roth P666.1 
Kinetex 2.6 u C18 100 Å, 150 x 2.1 mm phenomenex 00F-4462-AN 
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A.2.3 Devices 
Table A.2.3-1: Devices used in this study. 
Machine Model Company 
Air compressor CPM 160-8-6 W oilfree CompactMaster 
Autoclave 5075 ELV Tuttnauer 
Autoclave 3850 EL Tuttnauer 
Balance ABT 220-5DM Kern 
Balance Excellence XA 1502 S Mettler Toledo 
Balance Excellence XA 105 Dual Range Mettler Toledo 
Biosafety cabinet ESCO Class II biosafety cabinet biomedis 
Blotter Trans-Blot Turbo Transfer System BioRad 
Centrifuge uniCFUGE 2 LLG Labware 
Centrifuge Mikro 220R Hettich 
Centrifuge Rotina 420R Hettich 
Centrifuge Avanti J-26 XP Beckman Coulter 
Dishwasher Compact Desinfektor G7783 CD Mielabor Miele 
Electrophoresis 
Power Supply EV231 Consort 
Freezer  -20°C Froster Kirsch 
Freezer  -80°C 6343-6345/6383-6385 GFL 
GC-MS CT 1128 
Constellation 
Technology 
Corporation 
GC-MS Agilent 5977 Series GC/MSD System Agilent Technologies 
Gel Documentation 
Station 
VersaDoc Imaging System 
4000 MP BioRad 
Gel Electrophoresis 
Chamber Mini-PROTEAN Tetra System BioRad 
Hearing Protectors Sperian T1 Howard Leight 
Hearing Protectors Optime I Peltor 
Homogenizer M-110P Microfluidics 
Hotplate Stirrer Hotplate Stirrer Model L-81 Labinco 
Hotplate Stirrer VMS-A VWR 
HPLC ÄKTAPrime plus GE Healthcare 
HPLC SE04 system  ECOM 
HPLC UltiMate 3000 Dionex 
Ice Machine AF 80 Scotsman 
Incubator Heraeus Oven Thermo 
LC-MS/ Ion Trap Ultimate 3000/ amaZon ETD Dionex/ Bruker 
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Machine Model Company 
Lyophilizer / Freeze 
dryer RVC 2-33IR CHRIST 
Microplate Reader Eon Biotek Instruments 
Microwave Grill Hot Air Sharp 
Multichannel Pipette Rainin Pipet-Lite XLS 2-20 µl Mettler Toledo 
Multichannel Pipette Rainin Pipet-Lite XLS 20-200 µl Mettler Toledo 
PCR Cycler C1000 Thermal Cycler BioRad 
pH-Meter Seven Multi Mettler Toledo 
Photometer Specord 210 analytic Jena 
Pipette Rainin Pipet-Lite XLS 0.1-2 µl Mettler Toledo 
Pipette Rainin Pipet-Lite XLS 2-20 µl Mettler Toledo 
Pipette Rainin Pipet-Lite XLS 10-100 µl Mettler Toledo 
Pipette Rainin Pipet-Lite XLS 20-200 µl Mettler Toledo 
Pipette Rainin Pipet-Lite XLS 100-1000 µl Mettler Toledo 
Pipette Controller Rainin Pipet-X Mettler Toledo 
Purified Water System TKA-GenPure Thermo 
Refrigerator Super Kirsch 
Refrigerator MPR 1411PE Panasonic 
rosett cell  
Shake Incubator Multitron II Infors HAT 
Shaker Rocker 25 Labnet 
Thermo shaker TS-100 SC-20 bioSan 
Ultrasonic Bath Sonorex Bandelin 
Ultrasonic 
Homogenizer Sonopuls HD2200 Bandelin 
Ultrasonic 
Homogenizer 
Sonotrode 
MS 72 Bandelin 
Vortex VV3 VWR 
Water bath Microprocessor control MPC huber 
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A.2.4 Oligonucleotide Primers 
Table A.2.4-1: Oligonucleotide Primers used for P450 Fusion Construction. 
Primers for P450 Fusion Construction 
 
Construct Primer Name Primer Sequence 5'-3' 
pASK-
IBA33_CYP6
A1_BM3_KS 
CYP6A1_fw_KpnI CGCGGTACCAGCGTTGGAACTTTGGGTATTGGAAACGTCGTGGTATTCCGCATGAG 
CYP6A1_rev_linker+
SalI 
CCGGTCGACGGACTAGGGATCCCTCCGAG
GGGAATTTTCTTGCTTTTGATTTTCTTGCGA
ATTGC 
pASK-
IBA33_CYP6
A1_BM3_XS 
CY6A1d20_fwd_XbaI GGTATCTAGAatgagcCGTTGGAACTTTGGGTATTGGAAACGTCGTGGTATTCCG 
CYP6A1_rev_linker+
SalI 
CCGGTCGACGGACTAGGGATCCCTCCGAG
GGGAATTTTCTTGCTTTTGATTTTCTTGCGA
ATTGC 
pASK-
IBA33_CYP6
G1_BM3_KS 
CYP6G1_fw_KpnI 
CGCGGTACCAGCGCAATCACTCATACTGGC
AGCGTAAAGGGATTCCGTACATTCCGCCGA
C 
CYP6G1_rev_ 
linker+SalI 
CCGGTCGACGGACTAGGGATCCCTCCGAG
GGGAATTTTCTTGCTTTGAAGCGACGGAGC
TGATTG 
pASK-
IBA33_CYP6
G1_BM3_XS 
CYP6G1d20_fwd_ 
XbaI 
GGTATCTAGAatgagcCGCAATCACTCATACT
GGCAGCGTAAAGGGATTCCGTACATTCCG 
CYP6G1_rev_linker+
SalI 
CCGGTCGACGGACTAGGGATCCCTCCGAG
GGGAATTTTCTTGCTTTGAAGCGACGGAGC
TGATTG 
pASK-
IBA33_CYP6
AE14_BM3_
KS 
CYP6AE14_fw_KpnI 
CGCGGTACCAGAAGAAGAAATACCAGTATT
GGGAGAAACGCAAAGTTCCGCATCTCCCGC
CGGTG 
CYP6AE14_rev_SalI 
TCAGTCGACGGACTAGGGATCCCTCCGAGG
GGAATTTTCTTGCTATAGGCTTTCTCCAGGT
TC 
pASK-
IBA33_CYP6
AE14_BM3_
XS 
CYP6AE14d20_fwd_
XbaI 
GGTATCTAGAatgagcAAGAAGAAATACCAGT
ATTGGGAGAAACGCAAAGTTCCGCATCTCC
CGC 
CYP6AE14_rev_SalI 
TCAGTCGACGGACTAGGGATCCCTCCGAGG
GGAATTTTCTTGCTATAGGCTTTCTCCAGGT
TC 
pASK-
IBA33_CYP4
G1_BM3_KS 
CYP4G1_fw_delta_ 
KpnI 
CGCGGTACCAGGCACTTTATGAATATTGGC
GTCGCAACTCTCGCGAATATCGTATGGTTG
CAAATATTCCGTCGCCTCCGGAACTGCC 
CYP4G1_rev_Linker+
SalI 
CTGCTCAGTCGACGGACTAGGGATCCCTCC
GAGGGGAATTTTCTTGCTCGCAACAGTCGC
GTACTGG 
pASK-
IBA33_CYP4
G1_BM3_XS 
CYP_fw_universal_ 
XbaI_neu2 
GAGTTATTTTACCACTCCCTATCAGTGATAG
AGAAAAGTGAAATGAATAGTTCGACAAAAAT
CTAGAAATAATTTTGTTTAACTTTAAGAAGGA
GATATACAAATGGATTCAG 
CYP4G1_rev_Linker+
SalI 
CTGCTCAGTCGACGGACTAGGGATCCCTCC
GAGGGGAATTTTCTTGCTCGCAACAGTCGC
GTACTGG 
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Construct Primer Name Primer Sequence 5'-3' 
pASK-
IBA33_CYP4
G2_BM3_KS 
CYP4G2v1_fw_delta_
KpnI 
CGCGGTACCAGAGCCTGTACGAGATTTGGC
TCCGCAACACCCGTAAATACAAGCTGAC 
CYP4G2_rev_Linker+
SalI 
CTGCTCAGTCGACGGACTAGGGATCCCTCC
GAGGGGAATTTTCTTGCTCATTGCTTTCATG
GC 
pASK-
IBA33_CYP4
G2_BM3_XS 
CYP_fw_universal_ 
XbaI_neu2 
GAGTTATTTTACCACTCCCTATCAGTGATAG
AGAAAAGTGAAATGAATAGTTCGACAAAAAT
CTAGAAATAATTTTGTTTAACTTTAAGAAGGA
GATATACAAATGGATTCAG 
CYP4G2_rev_Linker+
SalI 
CTGCTCAGTCGACGGACTAGGGATCCCTCC
GAGGGGAATTTTCTTGCTCATTGCTTTCATG
GC 
pASK-
IBA33_CYP4
GF_Histag 
CYP4GF_fwd_EcoRI TCCCGAATTCATGTCTTTTGCGGACGCACTTGAAATGGTCGCAAC 
neu_CYP4GF_rev_ 
Histag_BamHI 
GGGATCCGTGGTGGTGATGGTGATGACCGG
CAATAGCCTTGCCACGATTTC 
pASK-
IBA33_CYP4
GF_BM3_KS 
dCYP4GF_fwd_KpnI 
CGCGGTACCAGTATATCTTTTATTATTGGTT
TTCAAGACGTCGTCTCAATGAAATGGCTTCA
AAAATTCC 
CYP4GF_rev_SalI 
TCAGTCGACGGACTAGGGATCCCTCCGAGG
GGAATTTTCTTGCTGGCAATAGCCTTGCCAC
GATTTC 
pASK-
IBA33_CYP4
GF_BM3_XS 
CYP4GF_fwd_XbaI 
TCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACAAATGTCTTTTGCGGACGCACTT
GAAATGGTCGCAACCAC 
CYP4GF_rev_SalI 
TCAGTCGACGGACTAGGGATCCCTCCGAGG
GGAATTTTCTTGCTGGCAATAGCCTTGCCAC
GATTTC 
pASK-
IBA33_CYP6
A1_BM3_XS
_shortLinker 
CY6A1d20_fwd_XbaI GGTATCTAGAatgagcCGTTGGAACTTTGGGTATTGGAAACGTCGTGGTATTCCG 
CYP6A1_rev_kurzer 
Linker+SalI 
CCGGTCGACGGACTTTTGATTTTCTTGCGAA
TTGC 
pASK-
IBA33_CYP6
G1_BM3_XS
_shortLinker 
CYP6G1d20_fwd_ 
XbaI 
GGTATCTAGAatgagcCGCAATCACTCATACT
GGCAGCGTAAAGGGATTCCGTACATTCCG 
CYP6G1_rev_kurzer 
Linker+SalI 
CCGGTCGACGGACTTTGAAGCGACGGAGCT
GATTG 
pASK-
IBA33_CYP4
G1_BM3_XS
_shortLinker 
CYP_fw_universal_ 
XbaI_neu2 
GAGTTATTTTACCACTCCCTATCAGTGATAG
AGAAAAGTGAAATGAATAGTTCGACAAAAAT
CTAGAAATAATTTTGTTTAACTTTAAGAAGGA
GATATACAAATGGATTCAG 
CYP4G1_rev_kurzer 
Linker+SalI 
CTGCTCAGTCGACGGACTCGCAACAGTCGC
GTACTGG 
pASK-
IBA33_CYP4
G2_BM3_XS
_shortLinker 
CYP_fw_universal_ 
XbaI_neu2 
GAGTTATTTTACCACTCCCTATCAGTGATAG
AGAAAAGTGAAATGAATAGTTCGACAAAAAT
CTAGAAATAATTTTGTTTAACTTTAAGAAGGA
GATATACAAATGGATTCAG 
CYP4G2_rev_kurzer 
Linker+SalI 
GCGCTCAGTCGACGGACTCATTGCTTTCAT
GGC 
pASK-
IBA33_CYP4
GF_BM3_XS
_shortLinker 
CYP4GF_fwd_XbaI 
TCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACAAATGTCTTTTGCGGACGCACTT
GAAATGGTCGCAACCAC 
CYP4GF_rev_kurzer 
Linker+SalI 
TCAGTCGACGGACTGGCAATAGCCTTGCCA
CGATTTC 
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Table A.2.4-2: Oligonucleotide Primers used for Sequencing. 
Sequencing Primers 
 
Vector Primer Name Primer Sequence 5'-3' 
pASK-
IBA33plus 
Seq_fwd_pASK GAGTTATTTTACCACTCCCT 
Seq_rev_pASK CGCAGTAGCGGTAAACG 
Seq_BM3CYP_rev_linker TCACGCGCAGTACCTTC 
SeqBM3_rev AGA ATC CAA AGT CGC AAC TTG 
pCDF-Duet-1 Seq_rev_pCDFDuet-1 GCTAGTTATTGCTCAGCGG Seq_fwd_pCDFDuet-1 GGATCTCGACGCTCTCCCT 
pET-Duet-1 
Seq_fwd1_pET Duet ATGCGTCCGGCGTAGA 
Seq_rev1_pET Duet GATTATGCGGCCGTGTACAA 
Seq_fwd2_pET Duet TTGTACACGGCCGCATAATC 
Seq_rev2_pET Duet GCTAGTTATTGCTCAGCGG 
 
Table A.2.4-3: Oligonucleotide Primers used for mRNA amplification. 
Primers for mRNA amplification 
 
Primer Name Primer Sequence 5'-3' 
fwd_kurz_CYP4G_Forfiucla TTCAAGTGGCCTCATTGATAAG 
rev_kurz_CYP4G_Forfiucla AACGGTGCATTCACTCATAAAG 
fwd_lang_CYP4G_Forfiucla CCTCATTGATAAGAATTG 
rev_lang_CYP4G_Forfiucla CGATTTATTTACCGATAAAC 
fwd_CYP4G_erweitert_Forficula CTTTATGAGTGAATGCACCGTT 
rev_CYP4G_erweitert_Forficula TATTTACCGATAAACAATAAAATAATTACATCAC 
rev_CYP4G_erweitert2_Forficula ACATCACTATTTATAAAATAAAATAAGGAATTGAAATATTAC 
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A.2.5 Restriction Enzymes 
Table A.2.5-1: Restriction Enzymes used in this study. 
Restriction Enzyme Supplier 
KpnI Thermo Fisher Scientific 
SalI Thermo Fisher Scientific 
XbaI Thermo Fisher Scientific 
NdeI Thermo Fisher Scientific 
BamHI-HF New England Biolabs 
NotI-HF New England Biolabs 
EcoRI-HF New England Biolabs 
NcoI-HF New England Biolabs 
KpnI-HF New England Biolabs 
SalI-HF New England Biolabs 
XbaI New England Biolabs 
Mph1103I (NsiI) Thermo Fisher Scientific 
HindIII Thermo Fisher Scientific 
XhoI Thermo Fisher Scientific 
PaeI Thermo Fisher Scientific 
AatII Thermo Fisher Scientific 
 
A.2.6 Culture Media 
 
Table A.2.6-1: Composition of E. coli Culture Media. 
Medium Supplier Catalog Number 
LB-Medium Roth 6673.1 
TB-Medium Roth 63237 
LB-Agar 1,5% Roth 
 
Additives for Expression Cultures 
1 M 5-Aminolevulinic acid 
1 M Thiamin 
2mM Riboflavin 
0.5 g/l FeCl3 
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Minimal Medium M9 
 
10x M9-Salts (pH7.2) 
337 mM NaH2PO4*2H2O  
220 mM KH2PO4 
85.5 mM NaCl 
93.5 mM NH4Cl 
 
M9-Medium 
1x M9-Salts 
3% Glucose 
1 mM MgSO4 
0.3 mM CaCl 
1 mM Thiamin 
1 mM 5-Aminolevulinic acid 
 
TSS-Medium 
10% PEG 
50 mM MgCl (6H2O) 
5% (v/v) DMSO 
ad. final volume LB-Medium 
 
A.2.7 Buffers 
Table A.2.7-1: Composition of 0.1 M Sodium Phosphate Buffer. 
0.1 M Sodium Phosphate Buffer (pH7.4) 
154.8 ml 1 M Na2HPO4 
45.2 ml 1 M NaH2PO4 
ad. 2000 ml dH20 
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Table A.2.7-2: Composition of Buffers used for Fusion Protein Purification at room 
temperature. 
IMAC Buffers for Fusion Protein Purification (RT) 
 
Lysis Buffer 1: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
 
Lysis Buffer 2: (pH7.5) 
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
2% CHAPS 
 
IMAC Buffer A: (pH7.5) 
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
30 mM Imidazole 
1% CHAPS 
 
IMAC Buffer B: (pH7.5) 
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
500 mM Imidazole 
1% CHAPS 
  
Anion Exchange Buffer A (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.1% CHAPS 
  
Anion Exchange Buffer B (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.1% CHAPS 
1 M NaCl 
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0.1 M Sodium Phosphate Buffer (pH7.4) (2000 ml) 
154.8 ml 1 M Na2HPO4 
45.2 ml 1 M NaH2PO4 
 
Table A.2.7-3: Composition of Buffers used for Fusion Protein Purification at 4°C. 
IMAC Buffers for Fusion Protein Purification (4°C) 
 
Lysis Buffer: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
 
Buffer A: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
30 mM Imidazole 
 
Buffer B: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
500 mM Imidazole 
  
Anion Exchange Buffer A (pH 7.4) 
20 mM Tris-HCl 
20% Glycerol 
  
Anion Exchange Buffer B (pH 7.4) 
20 mM Tris-HCl 
20% Glycerol 
1 M NaCl 
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Table A.2.7-4: Composition of Buffers used for hCPR Purification. 
Buffers for hCPR Purification 
 
Lysis Buffer Try 1: (pH7.5)  
100 mM NaCl 
30 mM Tris-HCl 
1 mM β-mercaptoethanol 
  
IMAC Buffer A Try 1: (pH7.5)  
100 mM NaCl 
30 mM Tris-HCl 
1 mM β-mercaptoethanol 
0.1 % CHAPS 
  
IMAC Buffer B Try1: (pH7.5)  
100 mM NaCl 
30 mM Tris-HCl 
200 mM Imidazole 
1 mM β-mercaptoethanol 
0.1 % CHAPS 
  
Lysis Buffer Try 2: (pH7.4) 
20 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.1 mM EDTA 
2 % Triton X-100 
2 % Na-Cholate 
  
IMAC Buffer A Try 2-6: (pH 7.4) 
50 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.15 M NaCl 
20 mM Imidazole 
Try 2: 1 %, Try 3-6: 0.5% Triton X-100 
Try 2: 1 %, Try 3-6: 0.5% Na-Cholate 
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IMAC Buffer B Try 2-6: (pH 7.4) 
50 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.15 M NaCl 
200 mM Imidazole 
Try 2: 1 %, Try 3-6: 0.5% CHAPS 
Try 2: 1 %, Try 3-6: 0 % Na-Cholate 
  
IMAC Washing Buffer (pH 7.4) 
50 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.15 M NaCl 
20 mM Imidazole 
1 % Triton X-100 
1 % Na-Cholate 
  
Ion Exchange Buffer A1: (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
  
Ion Exchange Buffer A2: (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
0.1 % CHAPS 
  
Ion Exchange Buffer B: (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
1 M NaCl 
0.1 % CHAPS 
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Table A.2.7-5: Composition of Buffers used for BM3 Purification. 
Buffers for BM3 Purification 
 
Lysis Buffer: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
  
IMAC Buffer A: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
  
IMAC Buffer B: (pH7.5)  
100 mM NaCl 
20% Glycerol 
30 mM Tris-HCl 
500 mM Imidazole 
  
Anion Exchange Buffer A (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
  
Anion Exchange Buffer B (pH 7.4) 
10 mM 0.1 M Sodium Phosphate Buffer 
20% Glycerol 
1 M NaCl 
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A.2.8 Stocks 
Table A.2.8-1: Antibiotics and other reagents and their applied and stock concentrations. 
Reagent 
Stock 
Concentration 
Solvent 
Applied 
Concentration 
Ampicillin 100 mg/ml de-ionized water 100 µ/ml 
Carbenicillin 100 mg/ml de-ionized water 100 µ/ml 
Streptomycin 50 mg/ml de-ionized water 50 µg/ml 
IPTG 1 M de-ionized water 1 mM 
Anhydrotetracyclin 2 mg/ml ethanol 0.2 µg/ml 
5-Aminolevulinic acid 1 M de-ionized water 0.5 mM 
Thiamine 1 M de-ionized water 0.5 mM 
FeCl3 0.5 mg/ml de-ionized water 0.25 µg/ml 
Riboflavine 2 mM de-ionized water 1 µM 
 
A.2.9 Kits 
Table A.2.9-1: Kits used in this study. 
Kit Supplier Catalog Number 
cDNA Synthesis Kit 
mRNA Isolation Kit Roche 11741 985 001 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 23225 
Quick Lyse Miniprep Kit Qiagen 27406 
Plasmid Plus Midi Kit Qiagen 12943 
GeneJet Gel Extraction Kit Thermo Fisher Scientific K0692 
Lumi-LightPlus Western Blotting Kit 
(Mouse/Rabbit) 
Roche 12015218001 
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A.2.10 Plasmids 
 
Figure A.2.10-1: Plasmid map of vector pASK-IBA33_BM3. 
 
Figure A.2.10-2: Plasmid map of vector pASK-IBA33_CYP6A1-BMR_KS. 
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Figure A.2.10-3: Plasmid map of vector pASK-IBA33_CYP6A1-BMR_XS. 
 
Figure A.2.10-4: Plasmid map of vector pASK-IBA33_CYP6A1-BMR_sL. 
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Figure A.2.10-5: Plasmid map of vector pASK-IBA33_CYP6G1-BMR_KS. 
 
Figure A.2.10-6: Plasmid map of vector pASK-IBA33_CYP6G1-BMR_XS. 
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Figure A.2.10-7: Plasmid map of vector pASK-IBA33_CYP6G1-BMR_sL. 
 
Figure A.2.10-8: Plasmid map of vector pASK-IBA33_CYP6AE14-BMR_KS. 
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Figure A.2.10-9: Plasmid map of vector pASK-IBA33_CYP6AE14-BMR_XS. 
 
Figure A.2.10-10: Plasmid map of vector pASK-IBA33_CYP4G1-BMR_KS. 
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Figure A.2.10-11: Plasmid map of vector pASK-IBA33_CYP4G1-BMR_XS. 
 
Figure A.2.10-12: Plasmid map of vector pASK-IBA33_CYP4G1-BMR_sL. 
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Figure A.2.10-13: Plasmid map of vector pASK-IBA33_CYP4G2-BMR_KS. 
 
Figure A.2.10-14: Plasmid map of vector pASK-IBA33_CYP4G2-BMR_XS. 
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Figure A.2.10-15: Plasmid map of vector pASK-IBA33_CYP4G2-BMR_sL. 
 
Figure A.2.10-16: Plasmid map of vector pASK-IBA33_CYP4GF-BMR_KS. 
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Figure A.2.10-17: Plasmid map of vector pASK-IBA33_CYP4GF-BMR_XS. 
 
Figure A.2.10-18: Plasmid map of vector pASK-IBA33_CYP4GF-BMR_sL. 
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Figure A.2.10-19: Plasmid map of vector pCDFDuet-1_AcylACPRed. 
 
Figure A.2.10-20: Plasmid map of vector pASK-IBA33_AldehydeDecarbonylase. 
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Figure A.2.10-21: Plasmid map of vector pASK-IBA33_hCPR. 
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